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Abstract 
Marine natural products are significant lead candidates for drug discovery. Among these marine 
natural products, two families of thiazole containing cyclic peptides (TCCPs), lissoclinamides (e.g. 
lissoclinamide 5) and patellamides (e.g. ascidiacyclamide), both isolated from Lissoclinum patella, 
have been of interest. These cyclic peptides display diverse biological activities and these were 
investigated after isolation and synthesis over the last 50 years. These compounds were found to 
bind various metal ions in nature, and this was proposed to contribute to the bioactivities observed 
for these types of compounds. The biological mode of action these molecules display, and the role 
of metal binding, are still unclear. However, based on the reported studies, the nitrogen atom of the 
thiazole participates in the metal chelation. Hence, a novel concept was proposed, based on a 
heteroatom interchange from nitrogen to sulfur through the interchange of carboxamide 
functionality from position 4 to position 5 of the thiazole ring system. The aim of this thesis is, 
firstly, the total synthesis of the heteroatom interchanged analogue of selected thiazole containing 
cyclic peptides, lissoclinamide 5 and ascidiacyclamide. Subsequently, metal binding studies and 
bioactivity tests were undertaken after the cyclic peptide analogues were successfully obtained. The 
total synthesis, together with metal binding and bioactivity studies, were expected to further the 
understanding of the biological mode of action these types of cyclic peptides display in addition to 
their role within the natural environment.  
 
The first selected target, heteroatom interchanged (HI) lissoclinamide 5 (1.143), was synthesised 
from the amino acids, valine, phenylalanine, proline, and threonine (chapter 2). The advanced 
intermediates towards HI-lissoclinamide 5 (1.143), that is 5-ester valine thiazole (2.16) and the 
5-ester phenylalanine thiazole (2.23), were obtained through two strategies. Two building blocks 
were formed separately from these two thiazoles, which were subsequently coupled together to give 
a linear peptide (convergent synthesis approach). The target cyclic peptide was obtained through 
cyclisation of the linear precursor. 
 
The synthetic strategy for the second target, HI-ascidiacyclamide (1.144), was similar to that 
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reported for the total synthesis of natural ascidiacyclamide (1.70), in which the target cyclic peptide 
was expected to cyclise through the dimerization of two identical building blocks (chapter 3). This 
significant building block, a tetrapeptide (i.e. 3.15), was successfully synthesised from D-threonine 
and L-isoleucine. However, the final cyclisation failed. An alternative route for the final cyclisation 
step was unable to be investigated due to time limitations, however, the amount of preliminary 
investigation provided in this thesis suggests the target will be obtained in the near future. 
 
Metal binding studies utilised mass spectrometry and circular dichroism (CD), whereas bioactivity 
studies, particularly anticancer evaluation, of HI-lissoclinamide 5 (1.143) was undertaken by our 
collaborator Prof. Peter Parsons at the Queensland Institute of Medical Research (chapter 4). It was 
discovered that HI-lissoclinamide 5 (1.143) can bind Cu(II) and associate with different halides. 
The metal binding study of the two building blocks (i.e. block B 2.49 and block A 2.53) of 
HI-lissoclinamide 5 (1.143) was undertaken in order to fully understand the metal binding process 
of HI-lissoclinamide 5 (1.143) itself. The results from anticancer studies suggested that 
HI-lissoclinamide 5 (1.143) exhibits a similar level of anticancer activity compared with its natural 
counterpart, lissoclinamide 5 (1.57). Moreover, the association with Cu(II) did not improve 
anticancer activity. 
 
The total synthesis of HI-lissoclinamide 5 (1.143), the associated metal binding and bioactivity 
studies, suggest that the heteroatom interchange from nitrogen to sulfur may not significantly affect 
the metal binding and anticancer activity compared to natural lissoclinamide 5 (1.57). Furthermore, 
the association of HI-lissoclinamide 5 (1.143) with Cu(II) does not affect the anticancer activity of 
this cyclic peptide. Although this study did not give an apparent answer to the biological mode of 
action of TCCPs, the successful total synthesis of HI-lissoclinamide 5 (1.143), especially the 
formation of the novel 5-ester thiazole (i.e. 2.16 and 2.23), has explored important concepts for 
future investigation in the area of TCCPs (chapter 5). 
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Chapter 1 General Introduction 
1.1  Natural Products and Drug Discovery 
Natural products are a valuable source of lead candidates for drug discovery. Newman and 
co-workers 1-4 determined that from the 1940s to 2007, 73% of the 155 small molecules approved as 
antitumor drugs did not originate from synthetic programs, among which 47% were natural 
products or direct derivatives thereof.  
 
In the review written by Newman and co-workers1 it was stated that from 1984 to 1995 more than 
60% of the anticancer and anti-infective agents were obtained or inspired from the natural 
environment, including outright natural products, those derived from semi-synthetic natural 
products, or synthetic compounds based on a natural product structural motif. It has been claimed 
justifiably that natural products constitute a significant portion of drugs in commercial use or 
development.1 Figure 1.11 shows examples of the known structure of drugs which are natural 
products or their derivatives. Active ingredients in U.S. prescriptions in 1973 constituted 25% 
derived from plants, 13.3% from microbes and 2.7% from animals. It was reported by Farnsworth et 
al. that at least 122 important drugs had been derived from 90 species of plants which were used as 
drugs worldwide, among the active elements of those plants 80% were identical or related to the 
traditional medicine used in Ayurveda, Unani, Kampo, and traditional Chinese medicine.5 In 1991, 
about half of the best selling pharmaceuticals were natural products or their derivatives. 
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An updated review4 by Newman and co-workers provided new data about the origin of drugs from 
1981 to 2006. The categories include biological product (B), natural product (N), derived from 
natural products (ND, semisynthetic modification), totally synthetic drug (S), totally synthetic 
product, but its pharmacophore is inspired by natural products (S*), vaccine (V), and natural 
product mimic (NM).  
 
Tables 1.1 and 1.2, and Figures 1.2 and 1.3 show that the natural product (N) and the compounds 
derived from natural products (ND) display significant roles across all anti-infective drugs and in 
the case of small molecule only anti-infective drugs.3 During 1981 to 2006, about 30% of new 
chemical entities (NCE) were totally synthetic drug (S), which indicated the significance of “other 
than formal synthetic” drugs in drug discovery.3  
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Table 1.1 All Anti-infective (Antibacterial, Fungal, Parasitic, and Viral) Drugs3 
Indication Total B N ND S S/NM S* S*/NM V 
Antibacterial 109  10 64 23   1 11 
Antifungal 29 1  3 22 3    
Antiparasitic 14  2 5 4  2  1 
Antiviral 78 12  2 7 1 20 12 25 
Total 230 13 12 74 56 4 22 13 37 
Percentage 100.0 5.7 5.2 32.3 24.5 2.2 9.6 4.8 15.7 
 
 
Figure 1.2 All new chemical entities from 01/1981 to 06/2006 (N=1184) (taken from Newman and 
Cragg3) 
Table 1.2 Small Molecule Anti-infective (Antibacterial, Fungal, Parasitic, and Viral) Drugs3 
Indication Total N ND S S/NM S* S*/NM 
Antibacterial 98 10 64 23   1 
Antifungal 29  3 22 3   
Antiparasitic 13 2 5 4  2  
Antiviral 41  2 7 1 20 12 
Total 180 12 74 56 4 22 13 
Percentage 100.0 6.7 41.1 31.1 2.8 12.2 6.1 
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Figure 1.3 All small molecule new chemical entities from 01/1981 to 06/2006 (N=974) (taken from 
Newman and Cragg3) 
 
There are some specific examples extracted from the data discussed above. Among approved small 
molecule drugs during 2003 to 2006, daptomycin (1.5) from Cubist, an antibacterial drug, is a 
natural product, whose biosynthetic gene cluster has been cloned and expressed. Tigecycline (1.6) 
from Wyeth, a tetracycline derivative, and carbapenem (1.7) are two examples of natural product 
derivatives. In the antifungal area, there is one derivative of a natural product, anidulofungin (1.8) 
which is an echinocandin derivative. In the antiviral area, there is one derivative of a natural product, 
enfuvirtide (1.9), one totally synthetic compound with the pharmacophore from a natural product, 
and four totally synthetic compounds with the pharmacophore from natural product mimics (Figure 
1.4). 
 5 
 
 
 6 
 
 
1.2  Marine Natural Products 
Among all the natural products, marine natural products have emerged as a very large, valuable and 
significant group of candidates in drug discovery. Those marine natural products are secondary 
metabolites produced in various marine organisms, especially invertebrates, including sponges, soft 
corals and molluscs (Figure 1.5).6  
 7 
 
 
The number of isolated marine products has grown continuously over the past 45 years.6 From 1977 
to 1987, approximately 2500 marine metabolites have been reported. Among which nearly 1700 
metabolites have been isolated during 1977 to 1985. In a subsequent year, 1987 to 1988, there were 
about 800 isolated metabolites. Among the marine invertebrates, during 1977 to 1987, 883 new 
compounds had been isolated from algae; 736 new metabolites were isolated from sponges; 560 
new compounds were produced by coelenterates; whereas only 65 new metabolites had been 
obtained from ascidians (Figure 1.6).6 
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Certain structural types were isolated from different kinds of invertebrates. For example, during 
1977 to 1985, coelenterates produced mainly terpenoids which is 85% of all metabolites it produced; 
among compounds isolated from sponges, terpenoids constitute only 37% and nitrogen containing 
metabolites constitute 41%. However, the major metabolites produced by ascidians are nitrogen 
containing metabolites, which is 89% of all its metabolites.6  
 
Because of the very significant bioactivity of nitrogen containing metabolites, the interest in 
ascidians increased significantly from 1988 to 1992, which gave approximately 165 new secondary 
metabolites. These compounds thus become the focus of synthetic campaigns and pharmacological 
discovery due to their complex structure and potent bioactivity (Figure 1.7).6  
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Cyclic peptides are a group of nitrogen containing metabolites that are a biologically important 
group of natural products. These cyclic peptides are produced in both marine and terrestrial 
cyanobacteria. The interest in these compounds arises as they display a diversity of very potent 
biological activity, including cytotoxicity, antitumor, antimalarial, antibacterial and allelopathic 
activity. Compared with terrestrial organisms, marine organisms are an enormous resource of cyclic 
peptides with interesting bioactivity.  
1.2.1 Cyclic Peptides from Cyanobacteria 
Cyanobacteria (blue-green algae, Chroococcales, Figure 1.8) are known as a source of bioactive 
cyclic peptides. It is a symbiont of various marine organisms. It has been reported that the bioactive 
cyclic peptides from marine organisms were actually produce by cyanobacteria. There are six 
families of cyclic peptides, which were reportedly isolated from cyanobacteria.7 
 
 
1.2.1.1 Antillatoxin 
Antillatoxin (1.10b), a cyclic lipodepsipeptide, was isolated in 2005 from the marine 
cyanobacterium Lyngbya majuscula collected at Curacao.8 The natural antillatoxin (1.10b) has 
ichthyotoxicity to gold fish and cytotoxicity to Neuro 2a cells by activation of the mammalian 
voltage-gated sodium channel (VGSC),9 and can produce neuronal death.10 The stereochemistry at 
C4 and C5 was firstly assigned as (4S, 5R) 1.10a according to the analysis of NMR spectrometric 
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data.8 However, this structure was revised to (4R, 5R) 1.10b by later synthetic efforts (Figure 
1.9).11-14 
 
 
1.2.1.2 Somamide A and Micropeptin T-20 
Two depsipeptides containing 3-amino-6-hydroxy-2-piperidone (Ahp) have been reported. One was 
somamide A (1.11), which was isolated in 2001 from the marine cyanobacteria Lyngbya majuscula 
and Schizothrix sp. collected on a Fijian island.15 The other was micropeptin T-20 (1.12) isolated in 
1999 from a freshwater cyanobacterium Microcyctis aeruginosa (Figure 1.10).16  
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1.2.1.3 Kahalalide F 
Kahalalides are a family of peptides containing cyclic or acyclic skeletons, which were isolated 
from the sacoglossan mollusc Elysia rufescens and the cyanobacterium Bryopsis sp.17-24 Kahalalide 
F (1.13) is the largest 19-membered cyclic depsipeptide of this family, which has antitumor activity 
and is in phase II clinical trials for the treatment of lung and prostate cancers, and melanoma.25 The 
stereochemistry at Val (3) and Val (4) of kahalalide F (1.13) was initially proposed to be opposite by 
two separate groups.26-27 The correct stereochemistry of Val (3) and Val (4) was confirmed by total 
synthesis.28 Interestingly, the biological activity of natural kahalalide F (1.13) with (R)-Val (3) and 
(S)-Val (4) was 10 times more active against than that of the diastereomer with (S)-Val (3) and 
(R)-Val (4) (Figure 1.11).28 
 
 
1.2.1.4 Apratoxins A-C 
Apratoxins A-C (1.14, 1.15, and 1.16), isolated in 2001 and 2002 from the cyanobacterium Lyngbya 
sp. collected at Guam29 and Palau,30 respectively. These cyclic peptides were found to exhibit potent 
cytotoxicity against KB cell and the LoVo cancer cell (IC50=0.52 and 0.36nM) (Figure 1.12).
7 
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1.2.1.5 Lyngbyabellins A and B 
Lyngbyabellins A (1.17) and B (1.18) were firstly isolated in 2000 from the cyanobacterium 
Lyngbya majuscula and exhibited anticancer activity against the human cancer cell lines.31-33 
Lyngbyabellin A (1.17) was found to exhibit moderate cytotoxicity against KB cells and LoVo cells 
(IC50=0.03 and 0.50μM),31 while Lyngbyabellin B (1.18) also exhibited cytotoxicity against KB 
cells and LoVo cells (IC50=0.10 and 0.83μM).33 Lyngbyabellins A (1.17) and B (1.18) are the first 
examples of cyclic peptides from cyanobacteria to contain multiple thiazole rings, which is related 
to this project (Figure 1.13).  
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1.2.1.6 Dendroamide A 
Dendroamide A (1.19), a cyclic peptide to contain the oxazole and thiazole rings, was isolated in 
1996 from the terrestrial cyanobacterium Stigonema dendroideum and was found to reverse drug 
resistance in tumor cells by over expressing either the transport proteins, P-glycoprotein or MRP 
(Figure 1.14).34 
 
 
To conclude, cyanobacteria produce various bioactive second metabolites. Lyngbya majuscula is the 
most common one.7 They contain the 2,4-substituted thiazole moiety and are usually quite 
biologically active.  
1.2.2 Cyclic Peptides from Sponges 
1.2.2.1 Microsclerodermins A - I 
Microsclerodermins A – I (1.20-1 – 1.20-9), a family of 23-membered cyclic peptides, were isolated 
between 1994 and 2000 from the both Theonella sp. and Microscleroderma sp., which exhibit 
antifungal activity and cytotoxicity (Figure 1.15).35-37 
 14 
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1.2.2.2 Phakellistatins 
Phakellistatins are a family of cyclic peptide metabolites isolated from the marine sponges of the 
genus Phakellia. Among these, phakellistatin 3 (1.21) and its diastereomer isophakellistatin 3 (1.22) 
were isolated in 1994 from the sponge Phakellia carteri. Phakellistatin 3 inhibited P388 leukemia 
cell growth (ED50=0.4μM) while its diastereomer isophakellistatin 3 (1.21) did not show any 
activity.38 The other cyclic peptide within this family, phakellistatin 13 (1.23), which was isolated in 
2003 from the sponge Phakellia fusca collected at Chinese Yongxing Island, exhibited cytotoxic 
activity against the human hepatoma BEL-7404 cell line (ED50<13μM).39 These three cyclic 
peptides exhibited different anticancer activities even though they have a very similar backbone 
conformation, and cyclic coordination sphere (Figure 1.16). 
 
 
1.2.2.3 Cyclotheonamides 
Cyclotheonamides A (1.24) and B (1.25) were isolated in 1990, whereas cyclotheonamides C-E 
were isolated in 1998 respectively from a sponge of the genus Theonella.40,41 The cyclotheonamides 
are 19-membered cyclic peptides. Acid hydrolysis gave five amino acid residues. These cyclic 
peptides showed inhibition activity towards serine proteases, among which, cyclotheonamide A 
(1.24) inhibited the aggregation of human platelet cells (IC50= 1.5μg/mL) (Figure 1.17).42 
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1.2.2.4 Papuamides A and B 
Papuamides A (1.28) and B (1.29), a type of cyclic depsipeptides, were isolated in 1999 from the 
marine sponge genus Theonella collected at Papua New Guinea. They displayed inhibition activity 
towards the infection of human T-lymphoblastanoid cells by HIV-1RF and anticancer activity against 
a number of human cancer cell lines (Figure 1.18).43  
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1.2.2.5 Halipeptins A and B 
Halipeptins A (1.30) and B (1.31), a family of 16-membered cyclic depsipeptides, were isolated in 
2001,44 whereas halipeptin C (1.32) was isolated in 2002,45 both from the marine sponge Haliclona 
sp. collected on the Vanuatu Islands. Halipeptin A (1.30) displayed significant antiinflammatory 
activity by reducing the edema of mice (0.3 mg/kg) (Figure 1.19).  
 
 
1.2.2.6 Jaspamide and Geodiamolides 
The cyclodepsipeptide Jaspamide (1.33) was isolated in 1986 from the marine sponge Jaspis sp.46,47 
and its homologues, geodiamolides A-F (1.34-1.39), were isolated during 1987 and 1994 from the 
marine sponge Geodia sp.48-51 as secondary metabolites. Jaspamide (1.33) has various bioactivities 
including cytotoxicity, antifungal activity, ichthytotoxicity, and insecticidal activity (Figure 1.20). 
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1.2.2.7 Keramamides 
The oxazole containing cyclopeptides orbiculamide A52 and keramamides B, C, D, 53 and E54 were 
isolated between 1991 and 1995 from the sponge Theonella sp. The keramamides, for example F 
(1.40), have thiazoles ring in place of the oxazole ring (Figure 1.21).54,55  
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1.2.3 Cyclic Peptides from Red Alga 
1.2.3.1 Ceratospongamides 
Two conformational isomers cis,cis- and trans,trans-ceratospongamides were isolated in 2000 from 
the Indonesian red alga (Figure 1.22) Ceratodictyon spongiosum, which contain the symbiotic 
sponge Sigmadocia symbiotica.56 trans,trans-Ceratospongamide (1.41) was reported to exhibit 
anti-inflammation activity, but cis,cis-cratospongamide (1.42) failed to show this activity. The 
stereochemistry of trans,trans-ceratospongamide (1.41) was revised to 
trans,trans-[D-allo-Ile]-ceratospongamide (1.43) by total synthesis (Figure 1.23).57,58 
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1.2.4 Cyclic Peptides from Ascidians 
Ascidians, a type of tunicate (sea squirts), whose larvae have notochords, are exclusively marine 
invertebrates. Ascidians are a valuable source of nitrogenous secondary metabolites. Most of these 
metabolites have various significant bioactivities, such as cytotoxicity, antitumor activity, anticancer 
activity, antiviral activity, and anti-inflammatory activity.  
1.2.4.1 Didemnins 
One of the most successful drug candidates is didemnin B (1.45), a cyclic depsipeptide isolated 
from the ascidian Trididemnum solidum.23 The didemnin family contains didemnins A-C (1.44, 1.45 
and 1.46) which were isolated in 1981.23 Didemnins D (1.47) and E (1.48) incorporate the same 
cyclic depsipeptide structure as didemnins A-C (1.44, 1.45 and 1.46), but their side chains contain 
two and three contiguous L-glutamines, respectively, and are terminated with a L-pyroglutamate 
residue.6 Another analogue of the didemnins, nordidemnin B (1.49), was also isolated.6 Didemnins 
X (1.50) and Y (1.51), contain three and four L-glutamine residues, respectively, and are terminated 
with a 3-hydroxydecanoyl unit.24 The didemnins exhibited significant biological activity, among 
which didemnin B (1.45) was the most active.59 It exhibited activity through inhibition of DNA and 
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RNA viruses, which can cause lethal diseases (e.g. Rift Valley fever, Venezuelan equine encephalo- 
myelitis, yellow fever, sand-fly fever, and a Pichinde virus).59 Didemnin B (1.45) also displays 
anticancer activity against P388 murine leukemia and B16 melanoma, and antitumor activity 
against ovarian, sarcoma, kidney, and breast cancer cells.59 Didemnin B (1.45) was the first marine 
natural product that entered clinical trials.59 However, didemnin B (1.45) failed to show any 
significant anticancer activity, but only toxicity when phase II human clinical trials was 
undertaken.59 The variability in biological activity of the didemnins depends on the acyl substitution 
pattern. For example, when the side chain is acetyl or longer, the cytotoxic activities are enhanced 
(Figure 1.24).60 
 
 
1.2.4.2 Lissoclinamides and patellamides  
Other important peptide metabolites are the Lissoclinum cyclopeptides. Two classes of 
cyclopeptides were isolated from the tunicate Lissoclinum patella, the heptapeptide lissoclinamides 
and the octapeptide patellamides/ulithiacyclamides.61 Lissoclinum patella, a type of ascidian, is in 
symbioses with prokaryotic algal cells.61 The cyclic peptides have been found in the isolated 
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symbionts of ascidians as well, so whether the host ascidians produce these cyclic peptides or 
symbionts algal cells synthesise them is still unknown.62 In both classes, small five membered 
heterocycles (oxazolines, oxazoles, thiazolines, and thiazoles) have been observed. Most of the 
lissoclinamides exhibit only mild cytotoxicity. The exceptions are lissoclinamide 7 (1.59) and 
lissoclinamide 4 (1.56) (cytotoxic against MRC5CV1 and T24 cell lines have IC50 values of 0.04 
μg/mL and 0.8μg/mL, respectively) (Figure 1.25).6 
 
The octapeptide patellamides/ulithiacyclamides includes patellamide A to E (1.63-1.69), 
ascidiacyclamide (1.70) and ulithiacyclamide (1.71) and ulithiacyclamide B (1.72). 
Ulithiacyclamide B (1.72) has a phenylalanine amino acid in place of an alanine in ulithiacyclamide 
(1.71). Ulithiacyclamide (1.71) has strong cytotoxicity to against L1210 leukemia cells (IC50=40 
ng/mL),61 but showed no selectivity against solid tumor cell lines,6 while patellamide D (1.66) was 
reported to be active against multiple drug resistance of a human leukemia cell line (Figure 1.25).63 
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1.2.4.3 Tawicyclamides A and B 
In 1992, new octapeptides, tawicyclamides A (1.73) and B (1.74), were isolated from Lissoclinum 
patella.6 The tawicyclamides (1.73 and 1.74) have one thiazoline and two thiazole ring systems, but 
without the oxazoline rings, which exist in all the previously discussed Lissoclinum peptides.64 The 
tawicyclamides (1.73 and 1.74) only have weak cytotoxicity against human colon tumor cells 
(IC50=30μg/mL), which demonstrated that the oxazoline ring was important for cytotoxicity (Figure 
1.26).65 
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1.2.4.4 Patellins 
A new family of cyclic peptides, patellins 1-5 (1.75-1.79), was isolated from Lissoclinum patella in 
1989,66(a) and patellins 6 was isolated from a Lissoclinum sp. in 1996.66(b) They do not contain 
thiazole or oxazoline rings, but contain a thiazoline ring system (Figure 1.27).66 Patellins 1-5 
(1.75-1.79) did not show any cytotoxicity in a series in vitro test, while Patellin 6 exhibited modest 
cytotoxicity against P388, A549, HT 29 and CV1 cells (IC50=2μg/mL) and showed inhibition of 
topoisomerase II (IC50=2.5μg/mL). 66(b) 
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1.2.4.5 Bistratamides and cycloxazoline (westiellamide) 
Three cyclic hexapeptides were isolated from the ascidian Lissoclinum bistratum collected from the 
Australian Great Barrier Reef.6 Among those, bistratamides A (1.80) and B (1.81) were isolated in 
1989, which contain both oxazoline and thiazoline rings.67 Bistramide A (1.80) contains a second 
thiazoline ring, whereas bistratamide B (1.81) has a thiazole ring. Both of them exhibited only weak 
cytotoxicity against the human MRC5CVl fibroblasts and T24 bladder carcinoma cells 
(IC50=50-100μg/mL).67 The other hexapeptide, cycloxazoline (1.82), was isolated in 1992, which is 
a symmetrical trimer containing three oxazoline rings and exhibited cytotoxicity against the human 
MRC5CVl fibroblasts and T24 bladder carcinoma cells (IC50=0.5μg/mL).68 This cyclic peptide had 
also been isolated in the same year from the terrestrial blue-green alga Westiellopsisprolifica and 
thus named westiellamide (Figure 1.28).69 
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1.2.4.6 Diazonamides 
Diazonamides A (1.83) and B (1.84) were isolated in 1991 from the ascidian Diazona chinensis 
collected in the Philippines.70 Diazonamide A (1.83) exhibited cytotoxicity against the human colon 
cancer HCT116 and B16 murine melanoma cell lines (IC50<15ng/mL) (Figure 1.29).
70 
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1.3  Thiazole containing cyclic peptides  
As detailed in the previous sections of this chapter, of the many marine natural cyclic peptides 
metabolites, the thiazole containing cyclic peptides (TCCPs) (Figure 1.30) constitute a large and 
important group. These cyclic peptides are produced in both marine and terrestrial cyanobacteria71 
and exhibit a range of size and complexity. The interest in these compounds, as highlighted, arises 
from the diversity of very potent biological activity, which includes cytotoxicity, antitumor, 
antimalarial, antibacterial and allelopathic activity.71-95  
 
One of the richest sources of TCCPs is the marine organisms of the Ascidiacea class (see section 
1.2.4), also referred to as tunicates, of which many live in symbiosis with cyanobacteria.71 The 
cyanobacteria provide the host with a complex mixture of TCCPs, which are non-toxic to the host, 
but are believed to protect the tunicate against predators.83-85 This selective toxicity is another 
important feature of these types of compounds in regards to searching for discriminating activity 
towards cancer cells compared to normal human cells. 
 
Furthermore, some TCCPs have been found to display reversal of multiple drug resistance (MDR) 
in cancer cells. The development of MDR in cancer cells is a major obstacle in successful treatment 
with chemotherapy.96-98 MDR is the resistance of tumors when treated with chemotherapeutic 
agents.98 The MDR phenotype was observed in many clinical samples and instigated many studies 
on them, especially in acute myeloid leukemia. One possible mechanism of MDR is that 
chemotherapeutic drugs are discharged by the multidrug resistance protein-1 (MDR1, 
P-glycoprotein), which was firstly raised by Ling in 1976.171 Another possible mechanism was 
considered. The reduction of drug accumulation and the increase of drug efflux caused by another 
protein, the multidrug resistance-associated protein (MRP). A third protein, the lung resistance 
protein (LRP) was also believed to contributed to MDR, which is a component in the cytoplasm and 
nuclear pore complexes, and a part of the bidirectional transport between the nucleus and 
cytoplasm.98 
 
Of the most potent drugs, both taxol (paclitaxel) and epothilone B (containing a thiazole ring), are 
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currently in use against MDR cancer cells, both are natural products or analogues of these (Figure 
1.32). Although very different in structure the mode of action of both compounds is disruption of 
micro tubulin.99 Many marine natural products were reported in clinical trials, among those cyclic 
peptides are a substantial portion.100 For example, kahalalide F (1.13) which acts on lysosomes, is in 
phase II clinical trials; didemnin B (1.45) and its dehydro-product are also in phase II clinical trials; 
diazoamides (1.83 and 1.84) which target tubulin has preclinical trial status (Figure 1.31). Although 
no TCCPs are yet to enter the clinic, many TCCPs, such as 1.17, 1.19, 1.57, 1.66, and 1.70, possess 
cytotoxicity against various strains of cancer cells, among them dendroamide A (1.19) and 
patellamide D (1.66) have induced reversal of MDR in cancer cell lines (Figure 1.30).85 
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1.3.1 Total synthesis of natural thiazole containing cyclic peptides 
Total synthesis of natural thiazole containing cyclic peptides is very essential to the confirmation of 
the structure of TCCPs, which were elucidated using different spectroscopic tools. More than 50% 
of the initially assigned structures, especially stereochemical assignments, of marine natural 
products were revised after total synthetic campaigns.61 Total synthesis can also provide sufficient 
quantities of material for further biological studies, and evaluating their role in the natural 
environment. 
 
The synthesis of these compounds is considered readily achievable in comparison to, for example, 
the much more complex structures of say taxol.7 In addition, TCCPs possess enhanced enzymatic 
stability and have a more rigid structure compared to “linear” peptides. Furthermore, they can 
potentially be administered orally since they are relatively lipophilic and have a relatively low 
molecular mass (400-1000 mass units). Microbial production of synthetically designed TCCPs in 
E.coli, is even possible through biochemical engineering.101 TCCPs therefore present a promising 
platform for future drug discovery, being part of the search for lead candidates aimed at facilitating 
clinical use. 
1.3.1.1 Total synthesis of ulicyclamide 
The first synthesis of ulicyclamide (1.53) was reported in 1985 by Schmidt et al. (Scheme 1.1).102 In 
this procedure, two thiazoles 1.87 and 1.90 were obtained through the Hantzsch thiazole synthesis 
methodology from two optically α-acyloxy thioamides 1.85 and 1.89 were reacted with ethyl 
bromopyruvate respectively. The reason for using optically active α-acyloxy thioamides instead of 
optically active α-acylamino thioamides, was due to racemisation being observed in the Hantzsch 
synthesis when using optically active α-acylamino thioamides. The two stereocentres of these two 
thiazoles were converted to the opposite enantiomer through Mitsunobu reaction to give thiazoles 
1.88 and 1.91. Those thiazoles 1.88 and 1.91 were coupled to give the tetrapeptide 1.92 through a 
redox reaction. The pentapeptide 1.93 was obtained through a Mitsunobu reaction, which turned the 
hydroxyl group into an amino group, and coupled with Boc-L-threonine followed by the cleavage 
of the two protective groups. The pentapeptide 1.93 was then condensed with 
Boc-phenylalanylproline imidic ester to provide the oxazoline heptapeptide 1.94. The ester in 1.94 
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was converted to an activated pentafluorophenyl ester, and the amine end was deprotected by 
treatment with acid. The final cyclisation was conducted in a 0.2 mM solution of hot dioxane with 
four equivalents of 4-pyrrolidinopyridine to provide the thiazole containing cyclic peptide 
ulicyclamide (1.53) in 20% yield. 
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1.3.1.2 Total synthesis of patellamide B 
The total synthesis of patellamides B (1.64) was reported by Hamada, Shibata, and Shioiri in 1985 
(Scheme 1.2),103 which revised the original structure assigned by Ireland and co-workers.104 In their 
synthesis, the D-phenylalanine-thiazole 1.95 and the D-alanine-thiazole 1.98 were coupled with 
L-allo-threonine to give the tripeptide 1.96 and 1.99, respectively. Then, the tetrapeptide 1.97 was 
prepared by coupling L-isoleucine with the tripeptide 1.96 using DEPC as the coupling reagent. 
Similarly, the tripeptide 1.99 was coupled with L-leucine to provide the second tetrapeptide 1.100. 
An octapeptide 1.101 was obtained through coupling the deprotected 1.97 and 1.100 with DEPC in 
79% yield. After saponification of the octapeptide 1.101 and removal of the Boc-protection, the 
deprotected linear peptide 1.101 was cyclized with excess DPPA to afford the cyclic precursor 
1.102 in 55% yield. The final thiazole containing cyclic peptide patellamide B (1.64) was obtained 
after the treatment of the cyclic precursor 1.102 with excess SOCl2 in 54% yield. 
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A second synthesis of patellamide B (1.64) was reported by Schmidt and Griesser in 1986 (Scheme 
1.3).105 The strategy in this method was different to the former in two parts. Firstly, the two routes 
disconnected the cyclic peptide at different positions. The former route103 disconnected the bond 
joining L-isoleucine and the D-alanine-thiazole, while the Schmidt and Griesser105 approach 
disconnected the bond connecting L-leucine and D-phenylalanine-thiazole. The second difference 
was that Schmidt and Griesser105 formed the two oxazolines before the macro-cyclisation. 
 
The first step in obtaining the two tripeptides 1.104 and 1.107 was conversion of the 
(S)-2-(1-hydroxyalkyl)-4-thiazolecarboxylic esters 1.103 and 1.106 through a Mitsunobu reaction 
into the corresponding amide (via azides). Then, the oxazoline tetrapeptides 1.105 and 1.108 were 
obtained by coupling the deprotected tripeptides 1.104 and 1.107, as amino alcohols, with the 
Boc-isoleucine imidic ester and the Boc-leucine imidic ester. The deprotected oxazoline 
tetrapeptides 1.105 and 1.108 were coupled to afford the linear octapeptide 1.109 by treating with 
DPPA in 65% yield. The target thiazole containing cyclic peptide patellamide B (1.64) was obtained 
after saponification of the linear octapeptide 1.109 and deprotection of the Boc group followed by 
cyclisation in high dilution (20% yield). Compared with the former strategy, the high sensitivity and 
volatility of the oxazoline ring was the main difficulty in the second strategy. 
 
 
 37 
 
 38 
 
In summary, both methods for the synthesis of patellamide B (1.64) formed the thiazole rings prior 
to the macro-cyclisation of the peptide so that the thiazole rings could restrict the conformational 
flexibility and facilitate ring closure.  
1.3.1.3 Total Synthesis of Ulithiacyclamide 
The first total synthesis of ulithiacyclamide (1.71) was reported by Kato, Hamada, and Shioiri in 
1986 (Scheme 1.4).106 Two different routes were adopted in their work, the first route was achieved, 
ultimately, through the cyclodimerization of the tetrapeptide, S-(acetamidomethyl)- 
-L-cysteine-L-allo-threonine-D-leucine-thiazole, 1.112. The second other route utilised a double 
cyclisation of the linear octapeptide 1.116, which contained a disulfide bond. In both strategies, the 
macro-cyclisation step gave the cyclic precursor 1.114, which was treated with SOCl2 in the final 
step to afford the unstable oxazoline rings, constructed from the L-allo-threonine residues. 
 
In the first route, the thiazole amino acid derivative, Boc-D-(leucine)thiazole-OMe 1.110, was 
coupled with Boc-L-allo-threonine-OH, then this tripeptide 1.111 was coupled with 
Boc-L-Cys(Acm)-OH to provide the tetrapeptide 1.112. All coupling steps used DEPC as the 
coupling reagent. The tetrapeptide 1.112 was cyclodimerized with DPPA to afford the macrocycle 
precursor 1.113 in 33% yield. The precursor 1.113 was deprotected and exposed to iodine to give 
the cyclic precursor 1.114 with a disulfide bridge in 90% yield. 
 
In the second strategy, the cyclic precursor 1.114 was prepared via a different route. Firstly, 
Boc-L-cystine 1.115 was coupled with the hydrochloride of deprotected tripeptide 1.111 to afford 
the linear precursor 1.116 in 73% yield, using DPPA as the coupling reagent. Alternatively, the 
linear precursor 1.116 could also be obtained in 96% yield by exposure of the tetrapeptide 1.117 to 
iodine. Then, the linear precursor 1.116 was hydrolysised with sodium hydroxide, and then 
deprotected with TFA at r.t. The cyclic precursor 1.114 was then obtained from the linear peptide 
1.116 with DPPA in 21% overall yield. 
 
After successfully obtaining the cyclic precursor 1.114 from either route, the oxazoline rings in 
ulithiacyclamide (1.71) were formed through the treatment with a large excess of SOCl2, which 
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gave ulithiacyclamide (1.71) in 71% yield. 
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1.3.1.4 Total Synthesis of Lyngbyabellin A 
The first total synthesis of lyngbyabellin A (1.17) was reported in 2001 by Yokokawa, Sameshima, 
and Shioiri.107 In their method, lyngbyabellin A (1.17) was disconnected at the peptide and ester 
bonds giving two thiazole fragments. The proposed route of this total synthesis was essentially 
condensation of these fragments and ultimate macro-cyclisation.  
 
The amide 1.116 was prepared through coupling of Boc-L-isoleucine 1.115 with 
N,O-dimethylhydroxyl amine using DEPC as the coupling reagent. The amide 1.116 was firstly 
reduced with lithium aluminum hydride and coupled with cysteine methyl ester to provide the 
thiazolidine 1.117, which was oxidised using CMD giving the L-isoleucine thiazole 1.118 (Scheme 
1.5). 
 
The commercially available aldehyde 1.119 was coupled with the cysteine methyl ester to provide a 
thiazolidine, which was dehydrogenated with CMD to give the thiazole methyl ester 1.120 in 7% 
yield. The yield was poor due to the volatility of the intermediate thiazolidine, although it was 
obtained in only two steps. Alternatively, thiazole 1.120 was achieved in a longer route, but with 
much higher yield. In this route, D-Fmoc-S-trityl cysteine 1.121 was converted into a methyl ester 
via TMSCHN2, and then the deprotected amine was coupled with 3-methylcrotonic acid. The 
obtained cysteine amide 1.122, was then deprotected and cyclized using titanium to afford the 
thiazoline 1.123. The latter was dehydrogenated with DBU/BrCCl3 to give the required thiazole 
1.120 in 81% yield. The methyl ester function in 1.120 was replaced with the TMSE group, giving 
α,β-dihydroxy thiazole 1.122 in 91% ee and in 90% yield on treatment with AD-mix-β (Scheme 
1.5). 
 
The enantioselective aldol reaction using a stoichiometric amount of the chiral oxazaborolidine 
1.125 and the ketene acetal 1.123 with the aldehyde 1.124 gave the dichlorinated β-hydroxy methyl 
ester 1.126 with excellent stereoselectivity (97% ee). The targeted β-hydroxy acid fragment 1.127 
was produced in 94% yield conversion to the allyl ester (Scheme 1.5). 
 
The tripeptide 1.129 was obtained by coupling the deprotected α,β-dihydroxy thiazole methyl ester 
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1.128 with Boc-glycine using DEPC. The hydrolysis product of tripeptide 1.129 was coupled with 
the β-hydroxy acid fragment 1.127 using DCC in the presence of DMAP to afford the depsipeptide 
1.130 in 90% yield. After the allyl group was removed with Pd(Ph3P)4 in the presence of 
morpholine, it was coupled with the α,β-dihydroxy thiazole 1.122 to provide the linear precursor 
1.131. The TMSE group at the C-terminus of the linear precursor 1.131 was removed using TBAF 
and the Boc group at the N-terminus deprotected using TsOH. The synthesis of lyngbyabellin A 
(1.17) was achieved in 58% yield from the deprotected linear precursor 1.131, and subsequent 
macro-lactamization using DPPA under high dilution conditions (Scheme 1.6). 
 42 
 
 
 43 
 
 
1.3.1.5 Total synthesis of dendroamide A 
The first total synthesis of natural dendroamide A (1.19) was reported by Bertram and Pattenden in 
2000.108 The oxazole amino acid 1.135 was prepared from Z-D-Ala-DL-Thr-OMe 1.133, which was 
oxidized with Dess-Martin periodinane. The oxazole 1.135 was formed through the cyclisation with 
triphenylphosphine and iodine, and then deprotected of the Cbz group. Thiazole 1.137 was prepared 
through a modified Hantzsch method by coupling ethyl bromopyruvate with the thioamide 1.136 of 
alanine. The oxazole 1.135 and thiazole 1.137 were coupled with EDCI-HOBt to afford tetrapeptide 
1.138, which was hydrolysed and coupled to give the linear precursor 1.140. Deprotection followed 
by macro-lactamization with FDPP/DIPEA afforded dendroamide A (1.19) in 91% yield (Scheme 
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1.7). 
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1.3.2 Metal binding studies of natural thiazole containing cyclic peptides 
As discussed previously within this chapter, among those biologically active marine cyclic 
peptides, thiazole containing cyclic peptides (TCCPs) constitute a very significant group, 
especially oxazoline-, thiazole-, and thiazoline-based TCCPs isolated from the species of 
ascidians, Lissoclinum patella and Lissoclinum bistratum.6 The mechanism of biological action, 
and role in nature, of these TCCPs is unknown, however these compounds have been found to 
bind metal ions (i.e. 1.142) (Figure 1.33).109-117 It was reported91,92 that the concentration of Cu(II) 
in marine ascidians is 10 times more than the sea water surrounding them despite the biotoxicity 
of Cu(II) itself. This fact gave rise to many questions surrounding the structure of potential 
complexes and how the metal ions influence the bioactivity of thiazole containing cyclic peptides. 
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The crystal structure of ascidiacyclamide with two Cu(II) ions (1.142) was first reported110 by 
Gahan et al. in 1994 (Figure 1.33). The metal complex was prepared from isolated natural 
ascidiacyclamide (1.70) and Cu(II). It has been shown from the crystal structure that the 
ascidiacyclamide (1.70) complex incorporates two Cu(II) ions and a carbonate bridge (1.142) 
(Figure 1.33).110 In this particular structure, the nitrogens in the oxazoline and thiazoles, and all 
the protons of the amides point towards the centre of the macrocycle. Moreover, six of the 
nitrogen atoms participate in metal chelation.110 The peptide carbonyls and alkyl residues are 
directed towards the outside of the macrocyclic ring. The X-ray crystal structure of this Cu(II) 
complex (1.142) showed that it has a saddle-shaped structure.110 Compared with the crystal 
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structure of ascidiacyclamide (1.70) itself obtained by Ishida et la.119 in 1987, which also 
presented a saddle-shaped conformation without intramolecular hydrogen bonds (Figure 1.33). 
Interestingly the bis-Cu(II) complex and the natural peptide both have the saddle-shaped 
conformation, with the complex only generating small changes in bond angles and lengths. 
However, some other analogous TCCPs without a metal bound have a more twisted conformation 
with internal hydrogen bonds,86 which has significant conformational difference with their metal 
complex.110 These results prove that TCCPs have conformational flexibility, but suggest that the 
conformational change upon ion binding is significant.115 This is one of the reasons why metal 
binding is believed to be important for the antitumor and antimicrobial activities displayed by 
TCCPs. Some reports also suggest that the metal complexes of TCCPs may function as 
oxidases121,122 and that TCCPs can act as calcium (II) carriers.113,114 More details and examples of 
the relationship between the conformation of TCCPs and their metal binding abilities will be 
discussed in chapter 4. 
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1.4  Research aim  
The goal of this project is to explore heteroatom interchanged thiazole containing cyclic peptides 
(HI-TCCPs) with regard to: (1) the synthesis, (2) the ability to bind metals, (3) the structure of the 
peptides with and without metal bound, and (4) examine anticancer activity as an indication for 
metal binding being important for activity. It is anticipated that the results of this project will be 
helpful to identify the relationships between conformation and bioactivities, the ability to binding 
metal ions, and metal complex and subsequent biological activity. 
1.4.1 The concept of heteroatom interchanged thiazole containing cyclic peptides 
(HI-TCCP) 
To date, all natural thiazole containing cyclic peptides have the carboxamide group placed at 
position 4 on the 1,3-thiazole ring system.71-86 The focus of this project is the interchange of 
carboxamide functionality from position 4 to position 5 of the thiazole moiety, producing a 
heteroatom interchange from nitrogen to sulfur (Figure 1.34). 
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Application of this concept to naturally occurring templates, containing 4-carboxy-thiazoles, 
affords structures that now direct the sulfur atom of each heterocyclic unit towards the cyclic 
cavity. The two chosen synthetic targets are shown above, HI-lissoclinamide 5 (1.143) and 
HI-ascidiacyclamide (1.144) (Figure 1.34). The interchange is expected to have major influence 
on metal chelation due to the very different features of sulfur and nitrogen in metal binding. 
Relatively few examples of complexes of thiazoles where the metal ion is coordinated through the 
sulfur atom have been reported.101 Due to the change in ion affinity which leads to change in 
conformation, some HI-TCCPs are expected to have increased activity compared to the natural 
compounds. Examination of the metal chelation of the HI-TCCP is therefore an essential part of 
this project. The metal binding properties of the HI-lissoclinamide 5 (1.143) and 
HI-ascidiacyclamide (1.144) and their biological activities will be compared to their natural 
counterparts, lissoclinamide 5 (1.57) and ascidiacyclamide (1.70). The positive or negative 
changes of metal binding abilities, and anticancer activities, are expected to provide information 
on whether metal complexation is involved in the anticancer activity of these compounds, with 
the end goal of trying to better understand MDR and the role of thiazole containing cyclic 
peptides in nature. 
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Chapter 2 Synthesis of HI-lissoclinamide 5 
2.1  Introduction 
2.1.1 Natural lissoclinamide 5 
As discussed in chapter one, lissoclinamide 5 (1.57) (Figure 2.1), a member of the lissoclinamide 
family, was first isolated from Lissoclinum patella in 1989 by Degnan et al.125 It was believed to 
be produced by a symbiotic prokaryotic algal cells of this ascidian, but not the ascidian itself. 
Acid hydrolysis of lissoclinamide 5 (1.57) suggested this cyclic peptide contains L-threonine, 
L-proline and L-phenylalanine. Excluding the stereochemistry of the three amino acid fragments, 
the stereochemistry of the two thiazoles was unknown. The stereochemistry was later confirmed 
through the first total synthesis of lissoclinamide 5 (1.57) by Pattenden in 1994.62 The anticancer 
activity of lissoclinamide 5 (1.57) was determined after the isolation.125 The IC50 for both control 
fibroblast cells and tumor cells (T24) are both lower than its family member lissoclinamide 4 
(1.56) (Figure 2.1) by two orders of magnitude. Lissoclinamide 4 (1.56), the other member of the 
lissoclinamide family, contains one thiazole and one thiazoline. It is only different from 
lissoclinamide 5 (1.57) by the thiazoline ring as opposed to a thiazole ring in lissoclinamide 5 
(1.57). This indicated that a thiazoline ring system may contribute to stronger cytotoxicity than a 
thiazole ring system in the thiazole containing cyclic peptides.  
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2.1.2  Total synthesis of natural lissocliamide 5 
Pattenden et al.62 reported the first total synthesis of lissoclinamide 5 (1.57). The synthetic 
strategy towards lissocliamide 5 (1.57) relied on thiazoles 2.2 and 2.4 (Scheme 2.1). 
 52 
 
In this strategy, the oxazoline ring was formed in the last step and the cyclic precursor 2.8 was 
disconnected to give a linear peptide 2.7, which was obtained by coupling the two peptide blocks 
2.5 and 2.6. The formation of the two thiazoles 2.2 and 2.4, which was afforded by condensation 
of the cysteine esters with carboximidates (imidates) 2.1 and 2.3 derived from L-valine and 
D-phenylalanine respectively. Then de-Boc L-valine thiazole 2.2 was coupled with 
L-allo-threonine to give the tripeptide 2.5, whereas the hydrolysis product of D-phenylalanine 
thiazole 2.4 was coupled with phenylalanine-proline methyl ester TFA salt to provide the 
tetrapeptide 2.6. The linear peptide precursor 2.7 was prepared by coupling the two building 
blocks 2.5 and 2.6. Hydrolysis followed by deprotection of the linear peptide 2.7, which was 
treated with DPPA for forming the peptide bond to give the cyclic precursor 2.8. The last step in 
the sequence was the oxazoline cyclisation with excess SOCl2 to afford the target natural product 
lissoclinamide 5 (1.57).  
 
To understand the biological mode of action of the thiazole containing cyclic peptides (TCCPs), 
the concept of heteroatom interchanged TCCPs (HI-TCCPs) introduced in chapter one was 
anticipated to be helpful to investigate whether the metal complexation would participate in the 
bioactivity of TCCPs. To achieve this aim, the total synthesis of HI-TCCPs was required. 
HI-lissoclinamide 5 (1.143) (Figure 2.2) was chosen as the first synthetic target. 
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2.2  Retrosynthesis of HI-lissoclinamide 5 
It was anticipated that the target analogue HI-lissoclinamide 5 (1.143) could be prepared in an 
analogous fashion to the total synthesis of natural lissoclinamide 5 (1.57) by Pattenden62 (Scheme 
2.1) using thiazoles with an ester at the 5 position in place of the 4 position (Figure 1.33). Final 
cyclic peptide HI-lissocliamide 5 (1.143) can be disconnected to a linear peptide 2.61a, which can 
be separated into two parts, the tetrapeptide block B 2.49b and the tripeptide block A 2.53a. Block 
B can be synthesized from a proline-phenylalanine dipeptide 2.45 and the 5-position ester 
phenylalanine thiazole 2.23b. Block A can be synthesized from commercially available 
L-allo-threonine and the 5-position ester valine thiazole 2.16a. The proline-phenylalanine 
dipeptide 2.45 can be derived from connection of L-proline methyl ester and Boc-phenylalanine. 
The hitherto unknown 5-ester thiazoles 2.23b and 2.16a should in turn be available from the 
known thioamides via a Hantzsch thiazole synthesis127-129 (Scheme 2.2). 
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2.3  Formation of key thiazoles 
2.3.1 Synthesis of thioamides 2.12 and 2.13 
Initially, attempts were made at forming the 5-position-thiazoles using L-phenylalanine and 
L-valine as starting materials, due to the higher price of commercially available D-phenylalanine 
and D-valine and problematic epimerisation (or racemisation), which was known to occur 
according to literature reports.127-129 
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Thiophenylalaninamide 2.12 was synthesized from commercially available L-phenylalanine 2.9 
following the published route.130-132 L-Phenylalanine 2.9, when treated with di-tert-butyl 
dicarbonate and sodium hydroxide, provided the Boc protected phenylalanine 2.10. Considering 
that the strong base sodium hydroxide might result in racemisation, the enantiomeric excess (ee) 
of compound 2.10 was evaluated (enantiomeric excess determinations was performed by the 
University of Queensland Enantioselective Chromatography Facility on a Daicel Chiralpak IA 
column (4.6 × 250 mm, Daicel Chemical Industries Ltd.)). The result showed no racemisation 
occurred during the reaction (ee 100%). Boc protected phenylalaninamide 2.11 was obtained in 
89% yield by treating 2.10 with ethyl chloroformate followed by aqueous ammonia. The target 
compound thiophenylalaninamide 2.12 was finally obtained in 60% yield from 2.11 after 
treatment with Lawesson’s reagent. The thiovalinamide 2.13 was synthesized using the same 
synthetic route described for 2.12. The overall yield, however, was slightly higher (63% over 
three steps) (Scheme 2.3).  
 
 
2.3.2 Hantzsch thiazole synthesis 
The first attempt at the synthesis of the 5-ester thiazoles 2.15 and 2.16 had applied the Hantsch 
thiazole synthesis, which had been previously undertaken in the Williams group. In this method, 
thiophenylalaninamide 2.12 and commercially available dicarbonyl 2.14 were heated in DMF 
overnight, as per the published procedure.133,134 Loss of the Boc protecting group was observed 
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and an unidentified thiazole product containing two ethyl esters was recovered. The pure product 
phenylalanine-thiazole 2.15 was obtained in just 11% yield and was totally racemized (ee 0%). 
Thioamide 2.13 and dicarbonyl 2.14 were stirred in DMF at r.t. for several days affording the 
desired valine-thiazole 2.16 in moderate yield (49%), but complete racemisation also occurred 
(Scheme 2.4). Modifications such as adding 4A molecular sieves or using basic conditions 
(pyridine/ethanol instead of DMF) led to thiazole 2.15 in only trace amounts. Racemisation was 
also observed when the Cbz-protected analogue of thioamide 2.12 was employed. The pure 
enantiomers of those thiazoles were obtained via preparative chiral HPLC, which however, 
increased the cost of the synthesis considerably, hence this method was abandoned. 
 
 
2.3.3 A new method for thiazole synthesis 
As the above route previously investigated by the Williams group gave 0% ee, another method 
was pursued. The new method was inspired by the synthesis of 2-aminothiazole-5-carboxylates 
reported by Zhao et al.135 In their strategy, 2-aminothiazole-5-carboxylates 2.20 was synthesized 
from ethyl β-ethoxy acrylate 2.17 and thioureas 2.19 (Scheme 2.5). Ethyl β-ethoxy acrylate 2.17 
was treated with NBS in water and dioxane to give an intermediate 2.18, 
α-formyl-α-bromoacetate hemiacetal, which was reacted with thioureas 2.19 in situ at 80oC to 
provide various N-substituted ethyl 2-aminothiazole-5-carboxylates 2.20 in moderate to high 
yields. 
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To achieve the desired 5-ester thiazoles, thioamides 2.12 and 2.13 were used in place of thioureas 
2.19 in Zhao’s strategy. This procedure would avoid interaction with the HCl (by-product), which 
could be a reason for significant racemisation.127-129 The mechanism of potential 
racemisation/epimerisation that could occur when forming thiazoles from enantiopure thioamides 
is show in Scheme 2.6. Therefore the proposed novel method was worth pursuing.  
 
 
In this strategy (Scheme 2.7), commercially available methyl β-methoxy acrylate 2.21 was reacted 
with NBS in water/dioxane (1/1) stirred at r.t. for 1h, showed by TLC that methyl β-methoxy 
acrylate 2.21 reacted completely to give the intermediate hemiacetal 2.22. Then, thioamide 2.12 
was added to the solution and stirred at r.t. overnight, which afforded the target 
thiazole-5-carboxylate 2.23 (ee 82%, yield 37%) along with by-product 2.24 (9%). The reason for 
the mild conditions (i.e. r.t.) instead of 80oC used by Zhao135, was because of the possibility of 
racemisation of the stereocentre. The same procedure was employed for the synthesis of 
thiazole-5-carboxylate 2.25 from thioamide 2.13. Unfortunately, the thiazole 2.25 was obtained in 
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only 8% yield and 37% ee. There was, however, a major by-product 2.26 isolated in 34% yield. 
The two by-products from these reactions were identical, but only different in the alkyl group, 
according to NMR and mass spectroscopy. Structure 2.26 was later confirmed by X-ray 
crystallography (Figure 2.3).  
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Attempts were made to optimise the reaction. Firstly, the reaction temperature was increased to 
60oC, which unfortunately did not improve the reaction outcome. Then, NBS was replaced with 
either NIS or NCS. The results showed that there was no target thiazole produced, but confirmed 
by-products 2.24 and 2.26 when using NIS. Moreover, NCS would not react with methyl 
β-methoxy acrylate 2.21 (Scheme 2.8). 
Figure 2.3 ORTEP representation of the X-ray crystallographic structure of 2.26 
(30% ellipsoid probability).  
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It was reported136 that thioamides 2.29 can react with NBS to give 3,5-disubstituted 
1,2,4-thiadiazoles 2.30 (Scheme 2.9). A possible mechanism for by-product formation was that 
the electrophilic brominium ion attacked the sulphur atom to give the sulfonium intermediate 2.31, 
which could react with another equivalent of itself. Subsequent loss of two hydrogen bromide 
equivalents successively afford the thiadiazole 2.30 (Scheme 2.9). 
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2.3.4 Synthesis of thiazoles by photolysis 
Due to the above failures a third approach to thiazole 2.16 was investigated. It had been reported 
by Prager137 that thiazoles of type 2.16 can be synthesized through the photolysis of 
isoxazole-4-carboxylate 2.35 in the presence of thioamides giving moderate yields (40-60%) of 
thiazole-5-carboxylate esters. 
 
To produce compound 2.35, N-phenylhydroxylamine 2.33 was required, which is usually obtained 
from the zinc mediated reduction of nitrobenzene.138 The crude product can be used directly for 
the ensuing reaction. Other reported methods139 were not as good. Commercially available diethyl 
ethoxymethylenemalonate and freshly prepared N-phenylhydroxylamine 2.33 were refluxed in 
ethanol in the absence of light for 24h.140 After re-crystallization from ethanol/ether, pure 
isoxazole-4-carboxylate 2.35 was obtained (yield 25%). A solution of compound 2.35 and 
thioamide 2.13 in CH3CN and 0.05% TFA was degassed and irradiated (carbene generation) under 
a nitrogen atmosphere at 254nm through quartz for 3h. The addition of acid (i.e. TFA) was 
essential so as to protonate the intermediate facilitating elimination of aniline, which was easily 
removed on work up with a 1M HCl wash (Scheme 2.11). Without TFA, a complicated mixture of 
products was obtained. Chromatography on silica gave the pure thiazole 2.16 (ee 33%, yield 62%). 
The same procedure was employed with thioamide 2.12 which afforded the desired thiazole 2.15 
(ee 25%, yield 60%) (Scheme 2.10). 
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2.3.5 Other methods attempted to access thiazoles 
Other methods that might have facilitated synthesis of the target thiazoles have been 
reported,141,142 but all attempts to develop these routes failed. 
 
It was reported by Fan et al.141 that 2-chloroacetamide when reacted with dimethyl 
acetylenedicarboxylate in the presence of DABCO, a tertiary amine base used as a potential 
catalyst, gave a Michael addition product. To achieve the desired product 2.37, the thioamide 2.13 
was used instead of 2-chloroacetamide and ethyl acetylenecarboxylate 2.36 was used instead of 
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dimethyl acetylenedicarboxylate (Scheme 2.12). However, the reaction failed. 
 
Ellman et al.143 reported that an arylboronic acid can react with N-tert-butanesulfinyl imines 
catalyzed by rhodium to give an imino ester. It was also reported142 that 2-bromo-1,3-thiazole 
2.38 can be reacted with aryl boronic acids in the presence of a palladium (0) to add aryl groups to 
the thiazole ring replacing bromide. In the designed strategy (Scheme 2.13), a 
2-bromo-1,3-thiazole 2.13 would react with a pinacol diboron 2.39 to give a 2-substituted-thiazole 
2.40, that would further react with butanesulfinyl imine to afford the desired aryl imino ester 2.41. 
However, this strategy failed at the first step. 
 
 
 
In conclusion, five methods were investigated for the synthesis of 5-carboxylate thiazoles. 
Considering method 2.3.2 (A) was abandoned, Table 2.1 shows that method 2.3.3 (B) and method 
2.3.4 (C) were the “best” options available. In the case of valine thiazoles 2.16 and 2.25, the ee 
from method B and method C were similar, however, comparing the yield, method C was far 
better. Comparing phenylalanine thiazoles 2.15 and 2.23, even though the yield of method B was 
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lower than method C, the satisfactory ee (82%) is the advantage of the method B. Therefore 
method B was the first choice in providing phenylalanine thiazole 2.15 (Table 2.1). 
 
Table 2.1 Comparison of thiazole synthetic methods using various amino acids 
 
 
Method (A) Method (B) Method (C) 
Amino acid Yield (%) ee (%) Yield (%) ee (%) Yield (%) ee (%) 
L-Valine 49 0 8 37 62 33 
Glycine - - 7 - 44 - 
L-Isoleucine - - 17 27 57 33 
L-Phenylalanine 11 0 46 82 60 25 
Method A (section 2.3.2): Hantzsch thiazole synthesis. 
Method B (section 2.3.3): New method using NBS. 
Method C (section 2.3.4): Photolytic method. 
2.4 Synthesis of the dipeptide 2.45 
L-Proline methyl ester hydrochloride 2.44 can be synthesized from commercially available 
L-proline 2.43 and SOCl2 in anhydrous MeOH. Concerned that the strong acid generated from 
SOCl2 would influence the ee of compound 2.44, the reaction was attempted with various acids 
and conditions. Firstly, the mixture was refluxed under argon for 1h.144 The mixture was stirred at 
0℃ for 1h and allowed to warm to r.t., and stirred overnight in the second method.145 SOCl2 was 
replaced by freshly distilled TMSCl in the third method, and the mixture stirred at r.t. 
overnight.146 The L-proline methyl ester hydrochloride 2.44 obtained from the three different 
reactions was used in the next step to synthesize dipeptide 2.45 respectively. The proton NMR 
gave the same spectra, indicating 2.44 probably does not undergo epimerisation (Scheme 2.14). 
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The known dipeptide 2.45 was prepared from L-proline methyl ester hydrochloride 2.44 and 
L-Boc-phenylalanine 2.10. However, the proton NMR of the dipeptide 2.10 showed that the 
nitrogen NH, the methyl ester and the Boc t-butyl group had peak doubling albeit at a ratio of 
about 1:4. The initial suspect was that any possible epimerization during the reactions gave rise to 
different diastereomers. To confirm whether the small signals arise from different diastereomers, a 
series of reactions were performed with different reagents, bases and solvents (Table 2.2).  
 
Table 2.2 Synthesis of dipeptide 2.45 from L-proline methyl ester hydrochloride 2.44 and 
L-Boc-phenylalanine 2.10 using different coupling reagents. 
 
Entry Coupling reagent Base Solvent Reaction time & temp. Yield 
1 DCC/HOBt166 NEt3 DCM 1h 0℃→r.t. overnight 57% 
2 HBTU167 DIPEA DMF Overnight & r.t. 44% 
2 T3P
168 TEA/DMAP DCM Overnight & r.t. 37% 
4 T3P
167 DIPEA DMF Overnight & r.t. 15% 
5 BOP NaHCO3 DMF 2h & r.t. 38% 
6 PyBOP157 DMAP DCM/DMF Overnight & r.t. 26% 
7 COMU154 TMP DMF 1h 0℃→r.t. overnight 80% 
8 COMU154 DIPEA DMF 1h 0℃→r.t. overnight 70% 
9 COMU154 TMP DMF 1h 0℃→r.t. 2h 85% 
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List of Table 2.2 abbreviations: 
BOP Benzotriazole-1-yl-oxy-tris-(dimethylami
no)-phosphonium hexafluorophosphate 
HOBt N-Hydroxybenzotriazole 
COMU (1-Cyano-2-ethoxy-2-oxoethylidenamino
oxy)dimethylamino-morpholino-carbeniu
m hexafluorophosphate 
HBTU 2-(1H-Benzotriazole-1-yl)-1,1,3,
3-tetramethyluronium 
hexafluorophosphate 
DCC Dicyclohexylcarbodiimide PyBOP (Benzotriazol-1-yloxy)tripyrroli
dinophosphonium 
hexafluorophosphate 
DCM Dichloromethane TEA Triethylamine 
DIPEA N,N-Diisopropylethylamine TMP 2,4,6-Trimethyl-pyridine 
DMAP 4-N,N-Dimethylaminopyridine T3P Propylphosphonic Anhydride 
DMF N,N-Dimethylformamide   
 
 
All reactions gave the same results in that the proton NMRs were the same albeit in different 
isolated yields. There are two possibilities. Firstly, all the different conditions gave the same 
extent of epimerisation, or secondly, the small signals seen in the proton NMR are the result of 
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rotamers.  
 
To examine the rotamer question, a variable temperature proton NMR experiment of dipeptide 
2.45 was undertaken in CDCl3. When the temperature increased to 45
oC or decreased to 10oC 
from 25oC, the position and ratio of the smaller signals did not change. When the solvent was 
changed from CDCl3 to toluene-d8 and increasing the temperature from 25
oC to 90oC, the signals 
finally coalesced indicating rotamers on the NMR time scale (Figure 2.5). 
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Even though it took some effort to prove the existence of rotamers, the series of reactions were 
helpful to identify the best conditions for the peptide coupling reaction. Considering the yield and 
the practicability of the procedure, the most efficient was COMU with TMP in DMF.  
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2.5 Synthesis of the tetrapeptide 2.49 (Block B) 
The standard protocol,147 using TFA in DCM, for removing a Boc protecting group when applied 
to the dipeptide 2.45 gave instead of deprotection cyclic dipeptide 2.46 in quantitative yield 
(Scheme 2.15). A similar reaction has been reported as an unwanted transformation during 
BOC-group removal.148-150 
 
 
 
The alternative protocol (MeOH/HCl derived from SOCl2) facilitated smooth removal of the Boc 
group from the dipeptide 2.45 with retention of the methyl ester, affording amine hydrochloride 
2.49 (yield 80%). Acid 2.48 (yield 83%) was prepared from thiazole 2.23 using hydroxide. 
 
Some experimentation was required to achieve a reasonable yield for the coupling step involving 
2.47 and 2.48. Pattenden147 used FDPP in his work with 4-carboxy thiazoles, but this reagent 
provided the tetrapeptide 2.49 in very low yields. Separation of the tetrapeptide 2.49 from FDPP 
by-products was also difficult. CMC151 failed to improve the yield, but moderate yields were 
achieved using the BOP reagent.152 
 
Two coupling methods were used to synthesize the tetrapeptide 2.49. In the first method, the 
mixture of amine 2.47, acid 2.48, BOP, NaHCO3 were sonicated for 2h in anhydrous DMF. This 
gave the pure tetrapeptide 2.49 as a white foam after purification by chromatography (yield 89%). 
NaHCO3 is critical as the base
153 for the coupling reaction involving BOP in order to avoid 
possible racemisation during coupling. The second method,154 involved amine 2.47, acid 2.48 and 
the coupling reagent COMU together with the base TMP in DMF (0oC for 1h and then at r.t. for 
2h) to give the compound 2.49 (88%). TMP has been described as a better base than DIPEA.154,155 
 71 
 
As the starting thiazole 2.23 contained a mixture of enantiomers (ee 82%), two diastereomers 
2.49a and 2.49b were obtained through HPLC (Scheme 2.16). 
 
 
 
The proton NMR of the tetrapeptide 2.49 showed that there was again signal doubling. To 
eliminate diastereomer formation through epimerisation and confirm beyond doubt rotamers, 
phenylalanine thiazoles 2.15 and 2.23 with different levels of enantiomeric access were applied to 
the synthesis of the tetrapeptide 2.49. Phenylalanine thiazoles from reaction 2.3.2 (ee 0%), 2.3.3 
(ee 82%) and 2.3.4 (ee 25%), were used in three separate reactions, respectively. In each case, 
after chromatography, the same material (other diastereomers removed by chromatography) was 
obtained according to the proton NMR.  
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Again increasing the temperature and running the proton NMR of the tetrapeptide 2.49 showed in 
toluene-d8 at 90
oC that the signals coalesced, which indicated beyond doubt the presence of 
rotamers, not diastereomers, arising from epimerisation (relevant 1H NMR spectrum of variable 
temperature experiment see Appendix A). Hence, the tetrapeptide 2.49 (Block B) was obtained as 
an enantiopure diastereomer. 
2.6  Synthesis of the tripeptide 2.53 (Block A) 
Boc-Amino acid 2.51 was prepared by the modified protocol156 from commercially available 
(L)-allo-threonine in 98% yield. The amine TFA salt 2.52 was prepared from the Boc thiazole 
2.16. Two methods were applied to the synthesis of the tripeptide 2.53 (Block A). In the first 
method, NaHCO3 was used as a base
153 for the coupling reaction with BOP and DMF as solvent. 
The mixture was sonicated for 2h. After chromatography, the compound 2.53 (Block A) was 
afforded in 42% yield. COMU, TMP and DMF were applied in the second method. The mixture 
was stirred for 1h at 0oC and 2h at r.t. Chromatography gave the pure Block A 2.53 (yield 60%). 
Again the two enantiomers from the starting thiazole 2.16 (ee 33%) gave two diastereomers 2.53a 
and 2.53b through HPLC (Scheme 2.17). 
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2.7  Confirmation of stereochemistry of the tripeptides 2.53a and 2.53b and 
the tetrapeptides 2.49a and 2.49b 
The specific optical rotations of the valine thiazole 2.16 and the phenylalanine thiazole 2.15 were 
measured to confirm the stereochemistry of the tripeptides 2.53a and 2.53b and the tetrapeptides 
2.49a and 2.49b. The results of the specific optical rotation are listed in Table 2.3 and Table 2.4. 
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Table 2.3 Specific Optical Rotation of the valine thiazoles 
 
Compound Specific O.R. 
(S)-valine thiazole* 
[α]D
23  − 20.54, C = 2.08% in Chloroform 
 
Valine thiazole (33% ee) 
[α]D
23  − 4.94, C = 2.08% in Chloroform 
 
Valine thiazole (37% ee) 
[α]D
23  − 9.35, C = 0.93% in Chloroform 
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Table 2.4 Specific Optical Rotation of the phenylalanine thiazoles  
 
Compound Specific O.R. 
(S)-phenylalanine thiazole* 
[α]D
23  − 26.03, C = 0.61% in Chloroform 
 
(R)-phenylalanine thiazole* 
[α]D
23  + 25.27, C = 0.61% in Chloroform 
 
Phenylalanine thiazole (82% ee) 
[α]D
23  − 16.30, C = 0.93% in Chloroform 
 
Phenylalanine thiazole(25% ee) 
[α]D
23  − 4.31, C = 0.58% in Chloroform 
 
 
*The pure enantiomers (S)-valine thiazole (2.54); (S)-phenylalanine thiazole (2.55); 
(R)-phenylalanine thiazole (2.56) were obtained by Chiral HPLC and the stereochemistry 
confirmed by X-ray crystallography (Dr. R. Grange, Williams group) (Figure 2.6, 2.7, and 
Scheme 2.18). 
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Figure 2.6 ORTEP representation of the X-ray crystallographic structure of 2.58 
(30% ellipsoid probability).  
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After comparing the specific optical rotation, the major enantiomer of the valine thiazoles 2.16 
(33% ee) and 2.25 (37% ee) is the (S)-enantiomer, due to the specific optical rotations of both the 
valine thiazoles 2.16 (33% ee) and 2.25 (37% ee) are negative compared with pure (S)-valine 
thiazole 2.54, which is also negative. The major enantiomer of the phenylalanine thiazoles 2.23 
(82% ee) and 2.15 (25% ee) is the (S)-enantiomer, due to the specific optical rotations of both the 
phenylalanine thiazoles 2.23 (82% ee) and 2.15 (25% ee) are negative compared with pure 
(S)-phenylalanine thiazole 2.55, which is also negative. As a result, the stereochemistry of the 
thiazole fragments within tripeptides 2.53 and tetrapeptides 2.49 have been confirmed based on 
the ratio of the two diastereomers obtained from the HPLC results is identical to the ratio of the 
starting enantiomers of the thiazoles. This result proved that the epimerisation of either 
stereocentre did not occur during the tri- and tetra- peptide coupling steps. The epimerisation only 
occurred in the thiazole synthesis step and this epimerisation is reasonable depending on the 
mechanism shown previously (Scheme 2.6). 
Figure 2.7 ORTEP representation of the X-ray crystallographic structure of 2.56 
(30% ellipsoid probability).  
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2.8  Synthesis of the linear peptide 2.61 
One pure diastereomer of Block A 2.53a and one pure diastereomer of Block B 2.49b were 
converted into the hydrochloride salt 2.59a and acid 2.60b respectively. Two methods were used 
to provide the linear peptide 2.61a from these two fragments. The first method involved 
sonication of the two fragments with BOP and NaHCO3 in DMF to provide the pure linear 
peptide 2.61a after chromatography (yield 47%). In the second method, the two fragments were 
stirred with COMU and TMP in DMF to provide the pure linear peptide 2.61a after 
chromatography (yield 70% over three steps) (Scheme 2.19). 
 
 
Accordingly, the other three diastereomers 2.61b, 2.61c, and 2.61d of the linear peptide 2.61a 
have been obtained using the preferred method (COMU and TMP in DMF) from different 
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combinations of two diastereomers of Block A 2.53a and 2.53b and two diastereomers of Block B 
2.49a and 2.49b (Figure 2.8). 
 
 
 
As seen before, the linear peptide 2.61a-2.61d shows rotamers in the proton NMR spectrum, but 
it is a single compound (i.e. Toluene-d8, 90
oC) (relevant 1H NMR spectrum is shown in Appendix 
A). In saying that, however, purification by HPLC is not straight forward and we believe that the 
rotamers seen on the NMR time scale caused difficulties with purification.  
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2.9  Synthesis of the cyclic peptide 2.63 
The linear peptide 2.61a was saponified with 1M NaOH to give a crude acid. The crude product 
was further converted to 2.62a using 50% TFA solution in DCM. According to mass spectrometry 
the reaction mixture contained one major component and as such was used in the next step 
without further purification. The first attempted method for the cyclisation of 2.62a to 2.63a was 
similar to the reported literature.157 The crude 2.62a was reacted with BOP/NaHCO3 in DMF to 
give a multi-component reaction mixture. Chromatography on silica provided a small amount of 
pure product 2.63a (yield 9%).  
 
A second method was performed due to the poor outcome of the above method. The thoroughly 
dried crude 2.62 was stirred with COMU and freshly distilled TMP in anhydrous DMF to provide 
the crude cyclic peptide 2.63a. Flash chromatography gave the pure product 2.63a (yield 40% 
over three steps). This method performed much better than the first (Scheme 2.20).  
 
On reflection the two coupling protocols, that is the combination of COMU and TMP performed 
identical to the combination of BOP and NaHCO3 when forming the building blocks, Block A 
2.53 and B 2.49. However, the former protocol was found to be much better than the latter 
combination when synthesizing the linear peptide 2.61 and the cyclic peptide 2.63. 
 
Subsequently, the other three diastereomers 2.63b, 2.63c, and 2.63d of the cyclic peptide 2.63a 
were obtained using the preferred method (COMU and TMP in DMF) arising from the other three 
diastereomers of the linear peptide 2.61b, 2.61c and 2.61d respectively (Scheme 2.20). 
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2.10 Synthesis of the final cyclic peptide 1.143  
Three methods of cyclodehydration were applied to achieve the final cyclic peptide 1.143a. The 
first method was a “traditional” method to form an oxazoline ring, which was reported by 
Pattenden147 when forming the oxazoline ring of the natural lissoclinamide 7 (1.59). In this 
method, the thoroughly dried cyclic peptide 2.63a was dissolved in anhydrous THF and Burgess’ 
reagent was added. According to the literature,147 the mixture was refluxed under argon for half an 
hour. However, the reaction was first stirred at r.t. There was no reaction at r.t. When the reaction 
was placed under reflux, after being stirred for 2 h, some of the target compound formed. The 
final cyclic peptide 1.143a was obtained after chromatography, although the yield was only 9%. 
 
Due to poor results with the first method, new reagents for forming oxazoline rings were 
applied.158 XtalFluor-E (Table 2.5) is a solid salt which is quite stable to overcome the shortage of 
Deoxo-Fluor which is explosive. Addition of XtalFluor-E to the solution of a thoroughly dried 
cyclic peptide 2.63a in anhydrous DCM at -17oC and then kept in the freezer (-24oC) overnight, 
followed by 0-4oC overnight. With these specific conditions the isolated yield of the final cyclic 
peptide 1.143a, after chromatography, was 50% (yield based on recovered unreacted starting 
material) (Scheme 2.21).  
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Because XtalFluor-E failed to give complete reaction, Deoxo-Fluor was investigated. 
Deoxo-Fluor when reacted with 2.63a in anhydrous DCM at -17oC and then kept in the freezer 
(-24oC) overnight, an isolated yield of 90% for the final cyclic peptide 1.143a was obtained. 
Results of three methods are summarised in Table 2.5. 
Table 2.5. Comparison of three methods to synthesise 1.143a (1-5mg scale). 
 
Reagent Structure of reagent Condition Isolated yield 
Burgess20 
 
THF, r.t. 24h→60oC 24h 9% 
XtalFluor-E44 
 
DCM, 0oC 72h 50% 
Deoxo-Fluor44 
 
DCM, -24oC 48h 90% 
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As shown in Table 2.5, the method using the Deoxo-Fluor reagent gave the best result. As a result, 
the Deoxo-Fluor reagent has been chosen as a standard reagent for the synthesis of the oxazoline 
ring in the final cyclic peptide. Accordingly, the three diastereomers 1.143b, 1.143c, and 1.143d 
of the HI-lissoclinamide 5 1.143a were obtained using the same conditions for all three 
diastereomers of cyclic peptide 2.63b, 2.63c, and 2.63d. All the diastereomers of the final product 
were purified by Chiral HPLC to secure purity, in case epimerisation would occur during the 
de-protection, hydrolysis, the peptide coupling and cyclisation steps.  
 
The structure, and stereochemistry, of the four HI-TCCP’s diastereomers (1.143a-d) was confirmed 
by 1H NMR, and 13C NMR, together with 2D NMR. NOESY spectra were used to confirm the 
stereochemistry of all diastereoisomers as anticipated from the synthesis. Diastereomer 1.143d will 
be discussed as an example of the stereochemical assignment processed utilised (Figure 2.9 to 
Figure 2.13). 
 
NOE spectra correlations H-C6/Ha-C7, H-C6/Ha-C8, and H-C6/Ha-C9 indicate that H-C6 (δH = 
4.42 ppm) resides on the same face as Ha-C7 (δH = 2.25 ppm), Ha-C8 (δH = 1.88 ppm), and Ha-C9 
(δH = 3.56 ppm). A NOE cross-peak between H-C2 (δH = 4.16 ppm) and H-C6 (δH = 4.42 ppm) 
confirmed the 2S* stereochemistry for the oxazoline/threonine moiety, which also supports the S* 
stereochemistry for C6 of the proline moiety utilised in the synthesis of 1.143d. A second NOE 
correlation between H-C5 (δH = 1.51 ppm) and H-C2 (δH = 4.16 ppm), together with the absence of 
a correlation between H-C3 (δH = 4.62 ppm) and H-C2 (δH = 4.16 ppm) confirmed the 3R* 
stereochemistry for the oxazoline/threonine moiety. The configuration of the valine moiety at C35 
was confirmed as R* based on the absence of a cross-peak between H-C35 (δH = 5.27 ppm) and 
H-C2 (δH = 4.16 ppm). The configuration of a phenylalanine moiety at C11 was confirmed as S* on 
the basis of a NOE correlation between H-C11 (δH = 4.72 ppm) and Ha-C9 (δH = 3.56 ppm) and the 
absence of correlation between H-C11 (δH = 4.72 ppm) and Hb-C9 (δH = 3.12 ppm). Moreover, the 
presence of a NOE cross-peak between Hb-C9 (δH = 3.12 ppm) and H-C14 (δH = 7.11 ppm), and the 
absence of a cross-peak between Ha-C9 (δH = 3.56 ppm) and H-C14 (δH = 7.11 ppm) also 
confirmed the 11S* stereochemistry (Figure 2.9 to Figure 2.13). However, among NOE spectra 
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correlations at C23 for all diastereomers, none could confirm the configuration of the phenylalanine 
moiety at the C23, because of the extended distance from other stereocentres. The 23S* 
stereochemistry was inferred from synthesis. 
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Figure 2.10 1H 2D NOESY NMR of 1.143d 
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Figure 2.11 1H 2D NOESY NMR (aromatic region) of 1.143d 
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Figure 2.12 1H 2D NOESY NMR (middle region) of 1.143d 
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Figure 2.13 1H 2D NOESY NMR (aliphatic region) of 1.143d 
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Chapter 3 Synthesis of HI-ascidiacyclamide 
3.1  Introduction 
3.1.1 Natural ascidiacyclamide 
As described in chapter one, ascidiacyclamide (1.70) (Figure 3.1), a thiazole containing cyclic 
peptide, was first isolated from an unidentified species of ascidian in 1983 by Hamamoto et al.159 
In a later report, this cyclic peptide was also isolated from Lissoclinum patella.125,126 The acid 
hydrolysis of ascidiacyclamide gave isoleucine and threonine.125,126 However, the stereochemistry 
of its amino acid moieties was not determined.  
 
 
3.1.2 Synthesis of natural ascidiacyclamide 
Hamada et al.160 reported the first total synthesis of natural ascidiacyclamide (1.70) in 1985. The 
stereo structure of this cyclic peptide was determined based on the synthetic result.160 The 
stereochemistry was later confirmed in 1987 by X-ray crystallography, which incidentally was the 
first X-ray obtained of a cyclic peptide isolated from an ascidian.119 
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In Hamada’s strategy160 (scheme 3.1), two amino acids, D-threonine 3.1 and L-isoleucine 3.2, 
were used as starting materials, and were thus coupled with DEPC to give a dipeptide 3.3. Then 
the 4-ester valine thiazole 3.4 was condensed with this dipeptide 3.3 to afford the tetrapeptide 
fragment 3.5. The following tetrapeptide 3.6 containing an oxazoline ring formed by treatment 
with SOCl2. The oxazoline stereo center required controlled epimerisation, because the cheaper 
D-threonine 3.1 was used instead of the much more expensive L-allo-threonine. Sodium ethoxide 
was used to effect the epimerisation step, affording the desired tetrapeptide 3.7. The 
cyclodimerization strategy was utilized to provide the final target ascidiacyclamide (1.70) using 
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DPPA as the coupling reagent. As reviewed in chapter one, most reported strategies regarding the 
synthesis of TCCPs obtained the peptide cycle from a linear precursor. Whereas, this 
cyclodimerization strategy is believed as a rare synthetic approach to this type of TCCPs, and no 
further reports have appeared.  
3.2 HI-ascidiacyclamide 
After the first target HI-lissoclinamide 5 (1.143) was successfully obtained as per discussion in 
chapter two, HI-ascidiacyclamide (1.144) was chosen as the second HI-TCCP target (Figure 3.2). 
In comparison to lissoclinamide 5 (1.57), ascidiacyclamide (1.70) has a larger cyclic cavity which 
may have a positive effect on metal binding. Furthermore, studies regarding cytotoxicity and 
metal binding of natural ascidiacyclamide (1.70) were reported109-117 as compared to natural 
lissocliamide 5 (1.57). The metal binding and anticancer studies of HI-ascidiacyclamide (1.144) 
would provide comparisons with those studies of its natural counterpart, and would suggest at the 
relationships between conformation of thiazole containing cyclic peptides, their metal binding 
capacities and their anticancer activities. 
 
 
3.2.1 Retrosynthesis of HI-ascidiacyclamide 
According to Hamada’s synthesis160 of natural ascidiacyclamide (1.70), a pathway to 
HI-ascidiacyclamide (1.144) was proposed (Scheme 3.2). 
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For the proposed synthesis, commercially available amino acid D-threonine 3.8 and L-isoleucine 
3.10 would be coupled to give a dipeptide 3.11. Instead of the 4-ester thiazole, 
HI-ascidiacyclamide requires 5-ester thiazole 2.52b, which would be coupled with dipeptide 3.11 
to give a tetrapeptide 3.13b. Due to the stereochemistry of the D-threonine fragment being 
different compared to natural ascidiacyclamide (1.70), the epimerisation of the oxazoline stereo 
center would be realized by treatment with strong base, e.g. sodium ethoxide. After obtaining the 
tetrapeptide 3.15b with the correct stereochemistry, HI-ascidiacyclamide (1.144) could be 
achieved by a cyclodimerization of two units of tetrapeptide 3.15b, due to the symmetric nature of 
the cyclic peptide.   
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3.3 Synthesis of the dipeptide 3.11 
The first fragment, the dipeptide 3.11, was synthesized from D-threonine methyl ester 3.9 and 
commercially available Boc-L-isoleucine 3.10. D-threonine methyl ester 3.9 was obtained from 
commercially available D-threonine 3.8 by treatment with SOCl2 in anhydrous MeOH at r.t. Then 
D-threonine methyl ester and Boc-L-isoleucine 3.10 were coupled with the coupling reagent 
COMU (the advantage of this coupling reagent along with the reaction conditions was discussed 
in detail in chapter 2) in anhydrous DMF in the presence of base (TMP) afforded the target 
dipeptide 3.11 in 64% yield (Scheme 3.3). 
 
 
3.4 Synthesis of the tetrapeptide 3.13 
The dipeptide 3.11 was hydrolyzed with sodium hydroxide in a mixture of MeOH, THF and water 
(2:2:1) at r.t. for 2 hrs. The 5-ester valine thiazole 2.16 (33% ee) was deprotected with TFA, and 
then the free acid 3.12 of dipeptide 3.11 was coupled with the free amine 2.52 of deprotected 
5-ester valine thiazole 2.16 to give the tetrapeptide 3.13 in 60% yield. The synthesis of thiazole 
2.16 was discussed in chapter 2. The choice of coupling method, that is using COMU and TMP in 
anhydrous DMF, was applied to this reaction. Two diastereomers were observed due to the two 
enantiomers arising from valine thiazole 2.16. The mixture of the two diastereomers was carried 
forward to the next step without purification (Scheme 3.4).  
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3.5 Synthesis of the tetrapeptide containing an oxazoline ring 3.14 
The oxazoline ring in the tetrapeptide 3.14 was formed through an oxazoline ring cyclisation 
method using the Deoxo-Fluor reagent reacted at -24oC for two days (the advantages of this 
method were discussed in chapter 2) from the tetrapeptide 3.13 in 90% yield. The described 
conditions for this reaction need to be strictly adhered to, for example, the solvent DCM was 
required to be freshly distilled; the reaction needs to be well sealed from the atmosphere and kept 
in the freezer (constant -24oC). An issue, however, arose in that only small scale reactions (2mg 
starting material in 1ml solvent) would completely react under these conditions, which, possibly, 
because the compound and the reagent in larger scale reaction could not react sufficiently without 
stir. Fortunately, no by-product was observed. The reason for this observation is unknown, but it 
could be associated with the quality of the reagent Deoxo-Fluor. Two diastereomers were 
observed due to the starting mixture containing two diastereomers (tetrapeptide 3.13). The 
mixture of two diastereomers were thus carried forward in the next step without further 
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purification (Scheme 3.5).  
 
3.6 Epimerisation of the tetrapeptide 3.14 to give a new tetrapeptide 3.15 
The oxazoline stereo center within the tetrapeptide 3.14 is opposite to the natural counterpart, and 
thus epimerisation of this stereo center was required. According to the reported method,160 sodium 
ethoxide was used to achieve this goal. However, to avoid hydrolysis of the ester by sodium 
hydroxide, anhydrous ethanol was required. Treatment of tetrapeptide 3.14 under reflux with 
freshly prepared sodium ethoxide smoothly afforded the epimerized tetrapeptide 3.15 in 90% 
yield. Two diastereomers 3.15a and 3.15b were observed, but this was anticipated due to the 
mixture of two diastereomers arising from the starting material (tetrapeptide 3.14), however these 
were separated by normal phase HPLC (Scheme 3.6). 
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The epimerisation step would not be required if L-allo-threonine, which contributes desired 
stereochemistry for the final target HI-ascidiacyclamide (1.144), could have been used to 
synthesize dipeptide 3.11 at the beginning of this strategy. However, the epimerisation step was 
successful and was believed to be a favorable strategy, especially due to the price of 
L-allo-threonine being much higher than D-threonine (Figure 3.3). 
 
 
3.7 Synthesis of HI-ascidiacyclamide 
Taking inspiration from the synthesis of ascidiacyclamide by Hamada (1.70),160 
HI-ascidiacyclamide (1.144) should be obtained by cyclodimerization of two equivalents of the 
tetrapeptide 3.15. The tetrapeptide 3.15 was firstly deprotected to give the free amine. Because of 
the acid sensitivity of the oxazoline ring, the general deprotection method using acid could not be 
used. The use of TMSOTf has been reported as a mild procedure for Boc deprotection.161 The 
presence of triflic acid would be detrimental to the oxazoline ring system, however, strictly 
anhydrous DCM and freshly distilled TMSOTf gave good results. The next step was hydrolysis to 
give the carboxylic acid 3.16b. The results of the mass spectroscopy of the two crude products 
from the Boc deprotection and the hydrolysis step strongly suggested the desired products were 
obtained (Scheme 3.7). 
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However, the deprotected free acid tetrapeptide 3.16b did not cyclize to give HI-ascidiacyclamide 
(1.144) using either methods involving DPPA as the coupling reagent. The first method used 
potassium hydrogen phosphate as the base, which was added together with DPPA into the 5mM 
solution of the tetrapeptide 3.16b in anhydrous DMF.160 In the second method, a mixture of 
sodium carbonate and sodium bicarbonate was added as base into the 13mM DMF solution of the 
tetrapeptide 3.16b.162 The NMR and MS results of the crude products and fractions from the silica 
column showed that neither of the desired cyclic peptide 1.44 nor any oligomeric products of the 
tetrapeptide 3.16b were observed.  
 
In the view of these disappointing results, another approach was contemplated, which involved, 
firstly, coupling two tetrapeptide 3.15 units to give a linear peptide 3.17. Equal equivalents of 
tetrapeptide 3.15 were treated with TMSOTf and NaOH to give the de-Boc and hydrolysis 
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product; they were then coupled by using the peptide coupling procedure with COMU and TMP. 
The linear peptide from this step contained Boc-protected NH and ethyl ester, which could be 
treated with NaOH and TMSOTf sequentially to give a linear peptide 3.17 with free amine and 
free acid. This could then be cyclized to give the desired cyclic peptide 1.144 by using COMU 
and TMP in a diluted DMF solution (i.e. concentration of 3mM). 
 
A third approach, which is similar to the route for the synthesis of HI-lissoclinamide 5 (1.143), is 
also feasible (Scheme 3.8). In this route, two equal equivalents of the tetrapeptide 3.13a would be 
de-protected and hydrolysed, then coupled to give a linear peptide 3.18. After de-protection and 
hydrolysis, the linear peptide 3.18 could be cyclized to give the cyclic peptide 3.19. The last step 
in this route is the cyclisation of the two oxazoline ring using Deoxo-Fluor reagent. 
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The difference between the second and the third approaches is the formation of the oxazoline ring. 
If the oxazoline ring was formed before coupling, the two diastereomers of tetrapeptide 3.15 
could be separated by normal phase HPLC, which would avoid formation of potentially four 
diastereomers of the linear peptide 3.17. However, the problem is that the oxazoline ring is acid 
sensitive. During later steps, a rigorous condition must be insured. For example, normal de-Boc 
acidic condition cannot be used, and during work-up, purification and NMR measurement, extra 
care is required to avoid any acidic condition to open the oxazoline ring. On the other hand, the 
third option to form the oxazoline ring in the last step avoids the drawback of the second option. 
However, because the two diastereomers of tetrapeptide 3.13 were difficult to separate via silica 
flash column or normal HPLC, chiral HPLC separation is required. Alternatively, four 
diastereomers of the targeted cyclic peptide 1.144 would require separation if the two 
diastereomers of tetrapeptide 3.13 were carried forward in later steps. Unfortunately, time did not 
permit full evaluation of the two proposed alternative routes. 
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Chapter 4 Metal Binding and Biological Studies 
4.1  Metal binding studies 
As discussed in chapter one, naturally occurring thiazole containing cyclic peptides were found to 
bind various metal ions, and this was proposed to contribute to the biological activity of these 
cyclic peptides.110 To investigate the connection between metal binding ability of TCCPs and their 
biological activity, extensive studies of the metal binding capacity of TCCPs has been conducted 
over the past 30 years.118 The most commonly studied TCCPs were the patellamide family (Figure 
4.1) and the lissoclinamide family (Figure 4.2). 
 
Members of patellamide family including ascidiacyclamide (1.70),110 patellamide A (1.63) and C 
(1.65),121 ulithiacyclamide (1.71),121 patellamide D (1.66),109 westiellamide (1.82)162,163 and their 
derivatives118,164&173 had been reported to bind with metal ions, in particular Cu(II) and Zn(II) 
(Figure 4.1, 4.2, and 4.3). On the other hand, in the lissoclinamide family, only two family 
members, lissoclinamide 9 (1.61) and 10 (1.62), 122 were reported to bind metal ions, again, Cu(II) 
and Zn(II). However, no metal binding studies of lissoclinamide 5 (1.57) have been undertaken 
yet.118 
 102 
 
 
 103 
 
 
 
 
4.1.1 Relationship between conformation of cyclic peptides and their metal binding 
activities 
Different cyclic peptides have varying abilities to bind a range metal ions. This phenomenon is 
believed to be a result of the different conformations that the cyclic peptides can adopt.118 For 
example, the X-ray crystal structures of ascidiacyclamide (1.70) and patellamide D (1.66) 
revealed that they have different conformations (Figure 4.4).118 Ascidiacyclamide (1.70) has a 
saddle-shaped conformation, in which the N-H of the amide and the N atom of the thiazole and 
oxazoline rings are directed towards the center of the macrocycle, and there are no intramolecular 
hydrogen bonds (Figure 4.5).118 However, patellamide D (1.66), which has the same back bone as 
ascidiacyclamide (1.70), was found to fold with a twisted “figure eight” conformation (Figure 
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4.4),118 in which there were four intramolecular hydrogen bonds, two were N-H…O=C and the 
other two were N-H…O (oxazoline) (Figure 4.5).118 
 
Figure 4.4 Sideviews of X-ray structures of (a) ascidiacyclamide and (b) patellamide D (taken 
from Comba118) 
 
 
Figure 4.5 Conformation of cyclic octapeptides (taken from Comba118) 
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4.1.2 Previous metal binding studies 
4.1.2.1 Patellamide D binding with Cu(II) 
Gahan et al.109 reported a metal binding study of patellamide D (1.66) (patH4), a member of 
patellamide family isolated from the ascidian Lissoclinum patella. It was reported that patellamide 
D (1.66) bound one Cu(II) to form various mononuclear Cu(II) complexes, in which three 
nitrogen atoms from the thiazole, oxazoline and amide moieties, respectively, were believed to 
participated in the metal chelation.109 It was suggested that the different mononuclear Cu(II) 
complexes had different metal ion binding sites.109 It was also found that patellamide D (1.66) 
bound two Cu(II) ions to form binuclear Cu(II) complexes (Figure 4.6).109 
 
 
4.1.2.2 The bis (Cu(II)) complex of ascidiacyclamide 
Gahan et al.110 also reported a metal binding study involving ascidiacyclamide (ascidH4) (1.70), 
also a member of patellamide family. In this study, a binuclear Cu(II) complex (Figure 4.7) of 
ascidiacyclamide (1.70) was formed and characterized by X-ray crystallography (Figure 4.8).110 
In this complex, three nitrogen atoms from the thiazole, oxazoline and amide moieties, in addition 
to a bridging functionality were coordinated with the Cu(II). The bridging entity CO3
2- was 
proposed to arise from the reaction of a Cu-OH moiety with carbon dioxide in the solution; no 
crystalline material formed when the reaction was conducted under an inert atmosphere with 
rigorous exclusion of carbon dioxide.110 
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Figure 4.8 X-ray structures of a binuclear Cu(II) complex of ascidiacyclamide (1.70) 
[Cu2(ascidH2)(1,2-μ-CO3)(H2O)2]•2H2O (taken from Gahan110). 
4.1.2.3 Patellamide A, patellamide C and ulithiacyclamide with Cu(II) and Zn(II) 
Morris et al.121 reported metal binding studies of patellamide A (1.63) and C (1.65), and 
ulithiacyclamide (1.71). Patellamide C (1.65) was found to bind either one or two equivalents of 
Cu(II). Binding with one Cu(II) changed the conformation from the “figure of eight” to the 
“square shaped” (Figure 4.5).118 Binding with two Cu(II) was observed in mass spectroscopy 
studies, however it was not observed by the circular dichroism (CD) studies. This suggested that 
the addition of second equivalent Cu(II) did not change the conformation of the peptide (Figure 
4.9)121. CD is a particularly powerful technique used to investigate the characteristics of metal 
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ions binding to amino acids or peptides123 as it is extremely sensitive to the effect of the metal ion 
on the conformation of the peptide ring, much more effective than, for example, UV-vis 
spectroscopy.124 Based on the CD studies it was proposed that, patellamide A (1.63) bound one 
Cu(II), however, unlike patellamide C (1.65), the binding did not cause a significant change of 
conformation.121 Ulithiacyclamide (1.71) was found to bind two Cu(II) also without any change to 
conformation. Moreover, Co(II), Ni(II), and Hg(II) were found not to coordinate to patellamide C 
(1.65).121  
 
A competitive binding study between Cu(II) and Zn(II) was undertaken by Morris et al.121 When 
two equivalents of Zn(II) ion were added to the solution containing one equivalent of patellamide 
C (1.65) and two equivalents of Cu(II) ion the CD spectrum was similar to that for the Cu(II) 
complex. However, on addition of two equivalents of Cu(II) ion to the solution containing one 
equivalent of patellamide C (1.65) and two equivalents of Zn(II) ion the CD spectrum was 
identical to that with only Cu(II) (Figure 4.9).121 This result suggested that the binding was 
selective for Cu(II). 
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Figure 4.9 CD spectrum of competitive binding of Cu(II) and Zn(II) to patellamide C (1.65) (0.02 
mg/mL) (taken from Morris121). 
4.1.2.4 Lissoclinamide 9 and 10 with Cu(II) and Zn(II) 
A metal binding study involving lissoclinamide 9 (1.61) and 10 (1.62) was reported by Morris.122 
The study with lissoclinamide 9 (1.61) showed that this cyclic peptide bound Cu(II), but not Zn(II) 
or Ni(II).122 The CD spectrum of lissoclinamide 9 (1.61) binding Cu(II) showed little observable 
change from that of the ligand itself, which suggested little or no conformation change occurred 
after binding Cu(II) (Figure 4.10).122 
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Figure 4.10 CD spectrum of lissoclinamide 9 (1.61) (0.02 mg/mL) with two equivalents of Cu(II), 
Zn(II), Ni(II), and a mixture of Cu(II) and Zn(II) (taken from Morris122). 
 
Lissoclinamide 10 (1.62) was found to bind with Zn(II) with no conformation change, and to bind 
with Cu(II) with conformation change.122 The CD spectrum of lissoclinamide 10 (1.62) with the 
mixture of Zn(II) and Cu(II) was identical to that with only Cu(II), which suggests that binding to 
Cu(II) is preferred over binding to Zn(II) (Figure 4.11).122 
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Figure 4.11 CD spectrum of lissoclinamide 10 (1.62) (0.02 mg/mL) with two equivalents of 
Cu(II), Zn(II) and a mixture of Cu(II) and Zn(II) (taken from Morris122). 
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4.1.3 Metal binding studies of HI-lissoclinamide 5 
After successfully obtaining HI-lissoclinamide 5 (1.143), metal binding studies were performed 
using CD, and mass spectroscopy. It was hoped that these results could lead to a better 
understanding of the biological mechanism, and whether metal binding is indeed important. 
4.1.3.1 Metal binding studies of building block B with circular dichroism (CD) 
To better understand the metal binding ability of the cyclic peptide HI-lissoclinamide 5 (1.143), 
the building blocks of this cyclic peptide were investigated by CD to help determine a specific 
binding model and overall determine whether the entire macrocycle is required for effective metal 
ion binding (Figure 4.12). 
 
 
 
When no base was added to the solution in MeOH containing one equivalent block B (2.49a) and 
two equivalents Cu(II) ion, there was no obvious change in the CD spectrum during gradual 
titration of the Cu(II) ion solution with the ligand solution (0.2 to 2 equivalents in 0.2 equivalent 
increments). This result suggested that no binding between block B (2.49a) and Cu(II) ion was 
present in the absence of base. 
 
However, when 0.2 equivalents of base (n-Bu4N)(OMe) solution was added, there was an 
apparent change in the CD (△ε) at 300 nm. However the △ε increased as the amount of base 
increased from 0.2 to 1 equivalent, suggested coordination of one Cu(II) ion to block B in the 
presence of base (Figure 4.13). 
 
 112 
 
 
Figure 4.13 CD spectra of the titrations of the base solution from 0 to 1 equivalent in 0.2 
equivalent steps to the solution of ligand (1 equivalent) and Cu(II) ion (2 equivalents). 
 
Prior to the addition of base, the solution of the ligand with Cu(II) ion was colourless. The color 
changed to light blue after the first 0.2 equivalent base was added suggesting the formation of a 
Cu(II) complex. After the addition of 1 equivalent of base, the solution became light green 
suggesting the formation of a different type of Cu(II) complex. 
 
The CD titration suggests that building block B (2.49a) could bind one Cu(II) ion in the presence 
of 1 equivalent of base. 
4.1.3.2 Metal binding studies of building block B with mass spectrometry 
The high resolution mass spectrum of block B (2.49a) with one equivalent of Cu(II) triflate 
solution showed a peak for [Cu (block B)]+ (found m/z 669.1800; calculated m/z 669.1808) 
(Figure 4.14). When the second or the third equivalent of Cu(II) solution was added to the 
solution, high resolution mass spectra only showed a peak representing [Cu (block B)]+, however, 
no peak for [Cu2 (block B)]
+ or [Cu3 (block B)]
+ was detected. 
 
Wavelength 
C
D
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In the negative mode of high resolution mass spectrometry block B (2.49a) was found to associate 
with Br
-
 (Figure 4.15), Cl
-
 (Figure 4.16), and I
-
 (Figure 4.17). 
 
 
Figure 4.14 The expansion of the high resolution mass spectrum (top) of the solution of one 
equivalent block B (2.49a) and one equivalent Cu(II) triflate together with the theoretical spectra 
(bottom) for block B - Cu complex. 
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Figure 4.15 The expansion of the high resolution mass spectrum (top) of the solution of one 
equivalent block B (2.49a) and one equivalent sodium bromide together with the theoretical 
spectra (bottom). 
 
 
Figure 4.16 The high resolution mass spectrum of the solution of one equivalent block B (2.49a) 
and one equivalent sodium chloride. 
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Figure 4.17 The high resolution mass spectrum of the solution of one equivalent block B (2.49a) 
and one equivalent sodium iodide. 
4.1.3.3 Metal binding studies of Cu(II) and building block A with mass spectrometry 
Mass spectrometry was also undertaken with block A (2.53a) to test whether this fragment could 
bind Cu(II) ions (Figure 4.18). 
 
 
The high resolution mass spectrum of block A (2.53a) with three equivalents of Cu(II) triflate 
solution showed a peak for [Cu (block A)]+ (found m/z 492.1145; calculated m/z 492.1230) 
(Figure 4.19). The result showed that block A (2.53a) can bind with one Cu(II) ion in solution. 
When the first two equivalents of Cu(II) solution were added to the solution, mass spectra did not 
show any indication of binding with Cu(II). 
 
In the negative mode of high resolution mass spectrometry block A (2.53a) was found to associate 
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with Br
-
 (Figure 4.20), Cl
-
 (Figure 4.21), and I
-
 (Figure 4.22). 
 
Figure 4.19 The expansion of the high resolution mass spectrum of the solution of one equivalent 
block A (2.53a) and one equivalent Cu(II) triflate for block A - Cu complex. 
 
 
Figure 4.20 The expansion of the high resolution mass spectrum (top) of the solution of one 
equivalent block A (2.53a) and one equivalent sodium bromide together with the theoretical 
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spectra (bottom). 
 
Figure 4.21 The expansion of the high resolution mass spectrum (top) of the solution of one 
equivalent block A (2.53a) and one equivalent sodium chloride together with the theoretical 
spectra (bottom). 
 
Figure 4.22 The low resolution mass spectrum of the solution of one equivalent block A (2.53a) 
and one equivalent sodium iodide. 
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4.1.3.4 Metal binding studies of HI-lissoclinamide 5 with mass spectrometry 
The low resolution mass spectrum of HI-lissoclinamide 5 (HI-lisH4) (1.143) showed that the 
major peaks included [(HI-lisH4).H]
+ (m/z 740.2), [(HI-lisH4).Na]
+ (m/z 762.2), and 
[(HI-lisH4).K]
+ (m/z 778.2) (Figure 4.23). The high resolution mass spectrum confirmed the 
molecular weight for [(HI-lisH4).Na]
+ (Found m/z 762.2503; Calculated m/z 762.2508).  
 
 
Figure 4.23 A low resolution mass spectrum of the HI-Lissoclinamide 5 (1.143) solution. 
 
After adding Cu(II) triflate solution, the low resolution mass spectrum showed [Cu (HI-lisH3)]
+ 
(m/z 801.1), and the high resolution mass spectrum gave [Cu (HI-lisH3)]
+ (Found m/z 801.1825; 
Calculated m/z 801.1828) (Figure 4.24). The result showed that the HI-lissoclinamide 5 (1.143) 
can bind with one copper in solution. However, there was still a strong [(HI-lisH4).Na]
+ (m/z 
762.2) peak after adding one equivalent of Cu(II) triflate solution. The [(HI-lisH4).Na]
+ (m/z 762.2) 
peak only decreased when two equivalents of Cu(II) triflate solution had been added. To 
investigated whether this result was due to sodium binding tighter than copper, one equivalent of 
sodium carbonate solution was added to the solution of the ligand with Cu(II) triflate solution. 
The mass spectrum showed that the [Cu (HI-lisH3)]
+ (m/z 801.1825) peak disappeared, suggesting 
that sodium binds preferentially to Cu(II) under the conditions in the mass spectrometer. 
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Figure 4.24 The expansion of the high resolution mass spectrum (top) of the solution of one 
equivalent HI-Lissoclinamide 5 (1.143) and one equivalent Cu(II) triflate together with the 
theoretical spectra (bottom) for HI-Lissoclinamide 5 - Cu complex. 
 
Zinc(II) acetate solution (one or two equivalents) and calcium carbonate solution (one or two 
equivalents), respectively, were added to a solution of the ligand. However, the low resolution 
mass spectrum showed no evidence of binding.  
 
In negative mode the low resolution mass spectrometry of HI-Lissoclinamide 5 (1.143) showed 
peaks at, [(HI-lisH3)]
-
 (m/z 738.4) and [(HI-lisH4).Cl]
-
 (m/z 774.3) (Figure 4.25). This result 
demonstrated that the ligand can associate with halide ions in the mass spectrum. To investigate 
this further, solutions of sodium fluoride, sodium chloride, sodium bromide, and sodium iodide 
were added, separately, to the ligand solution. Negative mode low resolution mass spectrum gave 
[(HI-lisH4).Br]
-
 (m/z 820.1) (Figure 4.25) and [(HI-lisH4).I]
-
 (m/z 866.1) (Figure 4.26), but no 
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signals were observed with fluoride. When sodium chloride solution was added to the ligand, the 
[(HI-lisH4).Cl]
-
 (m/z 774.3) signal increased and the [(HI-lisH3)]
-
 (m/z 738.4) signal decreased. 
 
 
Figure 4.25 A low resolution mass spectrum of the solution of one equivalent HI-Lissoclinamide 
5 (1.143) and one equivalent sodium bromide (negative mode) 
 
 
Figure 4.26 A low resolution mass spectrum of the solution of one equivalent HI-Lissoclinamide 
5 (1.143) and one equivalent sodium iodide (negative mode) 
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The metal binding study using mass spectrometry, along with the halide binding study indicates 
that the HI-lissoclinamide 5 (1.143) can bind Cu(II). There are a number of possible ways that this 
ligand could bind to one Cu(II) ion. Binding through the amide nitrogens, the thioether of the 
thiazole and/or the nitrogen donor of the oxazole are some possibilities. To fully understand this 
complexation further computational studies, and if possible isolation of a crystal of the complex, 
would be required. The possible binding mode of Cu(II) to HI-lissoclinamide 5 is shown in Figure 
4.27.  
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4.2  Biological studies  
The cytotoxicity of natural lissoclinamide 5 (1.57) has been reported.88 Two control cell lines 
(MRC5CV1 and lymphocytes) and one cancer cell line T24 (human bladder carcinoma) were 
used to test the cell viability under the effect of the cytotoxic compound lissoclinamide 5 (1.57).88 
The result suggested that lissoclinamide 5 (1.57) has only weak cytotoxicity (IC50 = 10 μg/mL for 
T24).88 However, lissoclinamide 4 (1.56) (IC50 = 0.8 μg/mL for T24) and 7 (1.59) (IC50 = 0.06 
μg/mL for T24), belong to the same lissoclinamide family with lissoclinamide 5 (1.57), have 
much stronger IC50 for the T24 cell line.
88 The only difference between these three cyclic peptides 
is that lissoclinamide 5 (1.57) has two thiazoles, whereas lissoclinamide 4 (1.56) has only one 
thiazole and one thiazoline, and lissoclinamide 7 (1.59) has two thiazolines and D-valine. 
Moreover, the cytotoxicity of a synthetic analogue of lissoclinamide 7 (1.59) with L-valine was 
reported165 (IC50 =8 μg/mL for K-562), which also had stronger anticancer activity than 
lissoclinamide 5 (1.57) (Figure 4.28 and Table 4.1 and 4.2).  
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Table 4.1 The IC50 data of lissoclinamide 4 (1.56), 5 (1.57), 7 (1.59) and 8 (1.60) against three 
different cell lines.88,165 
 
  
IC
50
 (μg/mL) 
 Lissoclinamide 
cell origin 4 5 7 8 
MRC5CV1 fibroblasts 1 15 0.04 1 
Lymphocytes  - 20 0.08 8 
T24 bladder cancer 1 10 0.06 6 
 
Table 4.2 Comparison of IC50 data for lissoclinamide 7 (1.59), and the three analogues (4.11-4.13) 
against selected cell lines.165 
 
IC
50
 (μg/mL) 
 Analogue 
cell Lissoclinamide 7 L-Val trisoxazoline tristhiazole 
HL-60 >75 6 >75 0.07 
K-562 70 8 >75 3 
RPMI-8226 15 8 >75 6 
HCC-2998 16 16 >75 8 
OVCAR-4 30 15 >75 8 
PC-3 30 16 >75 11 
MDA-MB-435 40 30 >75 10 
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In Table 4.1, against the three cell lines, lissoclinamide 7 (1.59) showed the highest toxicity, 
lissoclinamide 4 (1.56) and lissoclinamide 8 (1.60) showed much lower activity than the former 
one, followed by lissoclinamide 5 (1.57), which is the least active example among these four 
lissoclinamides. Although they have the same back bone, the differences are: lissoclinamide 5 
(1.57) has two thiazoles; lissoclinamide 4 (1.56) and lissoclinamide 8 (1.60) both have one 
thiazole and one thiazoline, but with opposite stereochemistry at the valine and the phenylalanine 
moieties; lissoclinamide 7 (1.59) has two thiazolines. Considering the biological results and their 
structure, it would suggest that the thiazoline ring contributes more to cytotoxicity than the 
thiazole ring. Moreover, lissoclinamide 4 (1.56) and lissoclinamide 8 (1.60) have identical 
connectivity, but differ by stereochemistry, which suggests that the difference in cytotoxicity 
could be caused by differences in conformation.  
 
The results presented in Table 4.2 indicated that the analogue (4.11) with L-Val of lissoclinamide 
7 (1.59) showed higher cytotoxicity than lissoclinamide 7 (1.59), which again demonstrated the 
relationship between conformation and biological activity. The tristhiazole analogue (4.12) had 
greatly increased activity compared to the trisoxazoline analogue (4.11), but also showed the 
highest cytotoxicity among these analogous cyclic peptides. This result suggests that the 
thiazoline ring contributes to the biological activity much more than the oxazoline ring system. 
 
To summarise, the contribution of the thiazoline ring to the cytotoxicity could be explained in two 
ways. Firstly, the contribution from the thiazoline, thiazole, or oxazoline rings is not due to the 
“toxicity” of these moieties themselves, but the different conformation of the macrocycle caused 
by the different heterocycles. The replacement of thiazole for thiazoline, or thiazoline for 
oxazoline could change the conformation of the cyclic peptide. Secondly, both conformation and 
heterocyclic rings, together with the different atoms (e.g. oxygen or sulfur), could directly or 
indirectly influence the metal binding ability of these cyclic peptides, thus changing their 
biological activity. However, these two possibilities are both unproven so far, and their 
relationships with the biological activity are unclear, which gives rise to the aim of this thesis, to 
investigate the relationship between conformation, metal binding, and bioactivity. 
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4.2.1 Biological activity of HI-lissoclinamide 5 
The comparison of the cytotoxicity of HI-lissocliamide 5 (1.143) with its natural counterpart 
lissoclinamide 5 (1.57) would provide information of whether the metal binding ability of this 
cyclic peptide contributes to its cytotoxicity. The interchanged heteroatom directs the sulfur atom 
towards the cavity of the cyclic peptide, which would change its metal binding ability due to the 
change in conformation. The difference between the cytotoxicity of HI-lissocliamide 5 (1.143) 
and the cytotoxicity of lissoclinamide 5 (1.57) would indicate that the different metal 
complexation lead to different cytotoxicity, hence suggest the relationship between metal 
chelation capability and bioactivity. The results of the growth inhibition of the different cancer 
cells by HI-lissoclinamide 5 (1.143) will be discussed and compared with the cytotoxicity of 
natural lissoclinamide 5 (1.57). 
 
The anticancer evaluation of HI-lissoclinamide 5 (1.143) was conducted by our collaborator Prof. 
Parsons (QIMR). The four diastereomers of HI-lissoclinamide 5 (1.143) were tested for their 
inhibition ability to various mammalian cancer cell lines, against a healthy human cell line. The 
results have been summarised in Table 4.3. 
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Table 4.3: Inhibition of cancer cell line growth by HI-lissoclinamide 5 (1.143) 
 
   
IC
50
 (μg/mL)* 
cell origin species C1 Natural2(b) C2 C3 C4 
NFF neonatal fibroblasts human 30 15 18 10 50 
Colo-205 colon tumor human 30 - 30 40 40 
HOP-62 lung cancer human 40 - 40 38 65 
K562 leukemia human 45 - 40 42 45 
MCF-7 breast cancer human 35 - 35 35 35 
SKMel-28 melanoma human 35 - 35 32 35 
T24 bladder cancer human 40 10 40 35 55 
B16 melanoma mouse 28 - 32 11 40 
*: C1-C4: HI-Lissoclinamide 5 (1.143a) and the corresponding three diastereomers 1.143b-d. 
 
Seven human tumor cell lines, a normal fibroblasts cell line and a murine melanoma cell line all 
responded similarly to prolonged treatment with the compounds (Table 4.3), giving IC50 values in 
the range of 11 to 65 μg/mL. The diastereomer (31R, 21R) was the most potent compound tested, 
giving an IC50 of 10 and 11 μg/mL for NFF and B16 respectively. The capability of these four 
diastereomers in killing cultured mammalian cells was similar to the natural counterpart, 
lissoclinamide 5 (1.57).88 However, this result is in contrast to the results of the bioactivity study 
of natural lissoclinamide 5 (1.57) reported by Degnan et al.62 
 
After the cytotoxicity results of HI-lissoclinamide 5 (1.143) were obtained, it was decided to 
ascertain the cytotoxicity of the Cu(II) complex of HI-lissoclinamide 5 (1.143). To achieve this 
Cu(II) triflate solution was added in the cyclic peptide solution. The results are shown in Table 
4.4. 
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Table 4.4: Inhibition of cell growth by HI-lissoclinamide 5 (1.143) with Cu(II) 
 
 IC50 (μg/mL)* 
Cell C1 C1+CuSO4 C1+Cu triflate C3 C3+CuSO4 C3+Cu triflate 
NFF 0.5 5 1.5 - 5 0.5 
MCF7 15 - - 8 - - 
SkMel28 20 18 18 21 16 37 
T24 90 80 40 60 75 70 
HT29 70 5 79 78 5 >100 
MM96L >100 2 >100 80 20 20 
*: C1: HI-Lissoclinamide 5 (31S, 21R); C3: diastereomer (31R, 21R). 
 
The results obtained show that MCF7 (10 μg/mL Cu(II) can inhibit 32% cell growth on average) 
and HT29, and probably MM96L were sensitive to inhibition by simple Cu(II) salts.169 Comparing 
with the cyclic peptides alone, in some cases such as with MM96L and HT29, the cyclic peptides 
most likely binding with Cu(II) seemed to counter each other rather than being synergistic for 
inhibiting cell growth. For example, when CuOTf was added with C1 and C3, the inhibition 
decreased, suggesting that the addition of Cu(II) salts did not facilitate inhibition of cell growth 
by the cyclic peptides. Two cell lines gave consistent results, SK-Mel28 with IC50 of about 20 
μg/mL for all treatments, and T24 60-80 μg/mL. The results indicated that the addition of CuSO4 
and CuOTf did not affect the inhibition of cell growth by the cyclic peptide itself. As the result of 
metal binding study showed that the HI-lissoclinamide 5 (1.143) can bind with one Cu(II), the 
mono- Cu(II) complex of HI-lissoclinamide 5 (1.143) exhibited the similar anticancer activity as 
HI-lissoclinamide 5 (1.143) itself. 
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Chapter 5 Conclusions and future directions 
 
The successful total synthesis of HI-lissoclinamide 5 (1.143) provided material to investigate the 
new concept of HI-TCCPs for metal binding and biological studies. The results of both studies 
have been compared to previous studies of natural lissoclinamide 5 (1.57) or analogous TCCPs. 
Our interest was whether there was any relationship between metal binding activity and biological 
activity in these HI-TCCPs.  
 
The metal binding results demonstrated that HI-lissoclinamide 5 (1.143) can bind one Cu(II) ion, 
but no binding with Zn(II) or Ca(II) was observed via mass spectroscopy. HI-lissoclinamide 5 
(1.143) was also observed to associate with halides, Cl
-
, Br
-
 and I
-
, in the negative mode of mass 
spectroscopy. The metal binding studies of lissoclinamide 9 (1.61) and 10 (1.62) by Morris,122 
suggested that the lissoclinamides can bind one Cu(II) ion, but could not bind to the second 
equivalent Cu(II). This suggests that the metal transportation behavior of TCCPs would not occur 
via binding between TCCPs and metal ions, however, the observed propensity of the HI-TCCPs 
to associate with halide ions may suggest a metal transportation mechanism involving the TCCP, 
a metal ion and a halide in an active halide-transportation process. 
 
Comparison of the anticancer activities of the four diastereomers of HI-lissoclinamide 5 (1.143) 
indicated that the different stereochemistry of the valine thiazole and phenylalanine thiazole do 
not influence the anticancer activity. As discussed in chapter five, lissoclinamide 4 (1.56) and 
lissoclinamide 8 (1.60),165 and lissoclinamide 7 (1.59) and its L-Val analogue88 showed similar 
cytotoxicity against different cell lines. The identical anticancer activities of the four 
diastereomers suggest a direct relationship between the bioactivity and conformation of the cyclic 
peptide. This is most likely based on the different stereochemistry of the side chain that does not 
alter the overall conformation of cyclic peptide. However, there is not sufficient substantive data 
to draw any definite conclusions concerning the relationship between side chains, conformation of 
cyclic peptides, and bioactivity of these cyclic peptides. Other methods, such as molecular 
modeling,126&165 will be helpful to study conformation of TCCPs in order to understand their 
metal binding mode. 
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The anticancer activity of HI-lissoclinamide 5 (1.143) (31S,21R), which has the same 
stereochemistry of natural lissoclinamide 5, has approximately the same anticancer activity 
compared to its natural counterpart. The cyclic peptide with or without Cu(II) ion has similar 
anticancer activity, which suggests that there is no synergistic inhibition.  
 
According to the discussion outlined in chapter four, the thiazoline ring displayed the major 
contribution, over the thiazole and oxazoline rings, with respect to the cytotoxicity of 
lissoclinamides. Moreover, the metal binding studies of lissoclinamide 9 (1.61) and 10 (1.62) by 
Morris122 indicated that lissoclinamide 10 (1.62) was more selective towards Cu(II) than 
lissoclinamide 9 (1.61). Both results give rise to the suggestion that the metal binding ability of 
the lissoclinamides relate to their biological activity, possibility because the lissoclinamides 
display stronger cytotoxicity, but also because the conformation facilitates easier metal ion 
binding. 
 
However, lissoclinamides were found to bind only one Cu(II), whereas patellamides can normally 
bind two Cu(II). It suggests the conformation seen in the patellamides bind metal ions easier. 
Thus, the second target of this thesis, HI-ascidiacyclamide (1.144), is important for studying 
metal binding and potentially relating that to biological activity, which would give more 
information on the relationship between metal binding and bioactivity. 
 
To conclude the above results, the results suggest that different thiazole moieties, either with 
nitrogen or sulfur atom towards the inside of the macrocycle, do not change either the biological 
activity or the metal binding ability. 
 
As only one HI-TCCP was studied in relation to metal binding and biological activity, it would be 
helpful to understand more fully the concept of HI-TCCP type compounds and the biological 
mode of natural TCCPs. Considering the synthesis of HI-ascidiacyclamide (1.144) was close to 
completion, new and more efficient synthetic strategies could be attempted. Successful synthesis 
of HI-ascidiacyclamide (1.144) would permit quantitative metal binding and biological studies. 
This will provide additional data to understand or support the significant of the HI concept.   
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Chapter 6 Experimental  
6.1 General experimental 
6.1.1 Solvent purification and source 
Anhydrous tetrahydrofuran was freshly distilled from sodium/benzophenone and anhydrous 
dichloromethane was freshly distilled from calcium hydride under argon. Anhydrous CH3CN, 
MeOH, ethanol, triethylamine, and 2, 4, 6-trimethylpyridine were distilled from calcium hydride 
under argon and stored over 4Å molecular sieves in Schlenk flasks. Anhydrous 
N,N-dimethylformamide was distilled from calcium hydride under reduced pressure at r.t. All 
distillation procedures were according to Armarego et al.170 Commercially available chemicals 
were purchased from Sigma-Aldrich Co. and commercially available amino acids were purchased 
from Mimotopes Pty Ltd. 
6.1.2 Reaction purification 
Column chromatography was undertaken with distilled solvents (distillation using the rotavapor) 
on silica gel (Flash Silica gel 230–400 mesh) or with a Biotage Isolera One (MPLC) with samples 
loaded onto a HP-SIL SNAP flash cartridge. Enantiomeric excess determinations and preparative 
chiral separator were performed by the University of Queensland Enantioselective 
Chromatography Facility on a Daicel Chiralpak IA column (4.6 × 250 mm, Daicel Chemical 
Industries Ltd.). Normal phase HPLC was performed with distilled hexane and ethyl acetate on 
column (Phenomenex Luna 5u Silica (2) 100A column, 250 x 4.6mm). 
6.1.3 Characterisation  
1H and 13C NMR data were recorded on Bruker AV300 (300 MHz; 75 MHz), AV400 (400 MHz; 
100 MHz), AV500 (500 MHz; 125 MHz) or AV900 (900.13 MHz; 226.36 MHz) instruments in 
deuteriochloroform (CDCl3) or toluene-d8. Coupling constants were given in hertz (Hz) and 
chemical shifts were reported in parts per million (ppm) on a δ scale relative to the solvent peak 
(1H, CDCl3 δ 7.24 ppm, Toluene-d8 δ 2.09 ppm, MeOD δ 3.31 ppm; 13C, CDCl3 δ 77.0 ppm, 
MeOD δ 49.15 ppm). The following abbreviations were used to indicate the multiplicity: s, singlet; 
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d, doublet; t, triplet; m, multiplet; br, broad. J values are in hertz.  
 
Low resolution electrospray ionisation mass spectrometry (LRESIMS) measurements were 
performed on a Bruker Esquire HCT (High Capacity 3D ion trap) instrument with a Bruker ESI 
source in positive ionisation mode. High resolution electrospray ionisation accurate mass 
spectrometry (HRESIMS) measurements were recorded on a Bruker MicrOTOF-Q 
(quadrupole-Time of Flight) instrument with a Bruker ESI source using sodium formate as 
reference calibrant in positive ionisation mode. 
 
Optical rotations were performed on a JASCO P-2000 polarimeter. 
 
The circular dichroism was measured with JASCO J-710 spectropolarimeter. 
 
Thin layer chromatography (TLC) was performed on silica gel 60 F254 aluminium sheets.  
6.2 Chapter 2 experimental procedures 
 
(S)-N-tert-(Butoxycarbonyl)phenylalanine (2.10) 
The literature procedure130 was followed. Boc2O (14.4g, 66mmol) followed by sodium hydroxide 
(4.8g, 120mmol) were added to a solution of commercial available L-phenylalanine (9.91g, 
60mmol) in THF (120mL) and H2O (120mL). The mixture was stirred overnight and then the 
THF was removed in vacuum. The aqueous phase was washed with Et2O (2×100mL), and then 
acidified to pH3 with 1M HCl solution. The product was extracted into DCM (2×150mL) and the 
combined organic phase was dried (MgSO4), and concentrated in vacuum to provide 
(S)-N-tert-(butoxycarbonyl)phenylalanine 2.10 as white foam (14.46g, 91%). The 1H NMR and 
13C NMR spectra matched that reported in the literature.132 
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1H NMR (300 MHz, CDCl3) δ ppm 7.33 – 7.09 (m, 5H), 4.92 (d, J = 7.9 Hz, 1H), 4.57 (m, 1H), 
3.16 (dd, J = 13.8, 5.4 Hz, 1H), 3.04 (dd, J = 13.9, 6.1 Hz, 1H), 1.40 (s, 9H).  
 
13C NMR (100 MHz, CDCl3) δ ppm 176.5, 176.0, 156.4, 155.4, 136.5, 135.8, 129.5, 129.4, 128.6, 
127.1, 126.9, 81.5, 80.3, 56.0, 54.2, 39.2, 37.8, 28.3, 28.0. 
 
 
(S)-N-tert-(Butoxycarbonyl)phenylalaninamide (2.11) 
The literature procedure131 was followed. Anhydrous triethylamine (7.68mL, 55.4mmol) followed 
by ethyl chloroformate (5.30mL, 55.4mmol) were added to a solution of 
(S)-N-tert-(butoxycarbonyl)phenylalanine 2.10 (14.69g, 55.4mmol) in anhydrous THF (500mL) 
at 0oC under argon. The mixture was stirred in an ice bath for 1h and then concentrated aqueous 
ammonia (28%, 45mL) was added. The ice bath was removed and the mixture stirred for 1h. THF 
was removed in vacuum and the residue was diluted with water (60mL) and the product was 
extracted into EtOAc (3×200mL). The combined organic phase was washed with sat. NaHCO3 
(1×250mL), 10% citric acid (1×250mL) and brine (1×250mL) and dried (Na2SO4) and 
concentrated in vacuum to provide (S)-N-tert-(butoxycarbonyl)phenylalaninamide 2.11 as a white 
foam (18.89g, 89%). The 1H NMR spectra matched that reported in the literature.132 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.42 – 7.05 (m, 5H), 5.90 (s, 1H), 5.69 (s, 1H), 5.08 (d, J = 7.9 
Hz, 1H), 4.35 (m, 1H), 3.04 (d, J = 6.6 Hz, 2H), 1.38 (s, 9H). 
 
LRMS (ESI): Calculated for C14H20N2O3 Na
+ 287.32 Found 287.14. 
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(S)-N-tert-(Butoxycarbonyl)thiophenylalaninamide (2.12) 
The literature procedure132 was followed. Under an argon atmosphere, Lawesson’s reagent 
(17.35g, 42.9mmol) was added to solution of (S)-N-tert-(butoxy-carbonyl)phenylalaninamide 
2.11 (18.89g, 71.5mmol) in anhydrous THF (350mL) and the mixture was stirred overnight at r.t. 
EtOAc (700mL) was added and the solution was washed with sat. NaHCO3, H2O and brine 
(1×40mL each). The organic phase was dried (Na2SO4) and concentrated in vacuum. Flash 
chromatography (silica gel, petroleum ether: ethyl acetate 2:1, Rf=0.66) provided 
(S)-N-tert-(butoxycarbonyl)thiophenylalaninamide 2.12 as a white foam (11.89g, 60%). The 1H 
NMR spectra matched that reported in the literature.132 
 
1H NMR (300 MHz, CDCl3) δ ppm 7.48 (br s, 1H), 7.44 (br s, 1H), 7.36 – 7.14 (m, 5H), 5.40 (d, J 
= 7.9 Hz, 1H), 4.67 (m, 1H), 3.14 (d, J = 7.0 Hz, 2H), 1.37 (s, 9H). 
 
LRMS (ESI): Calculated for C14H20N2O2SNa
+ 303.39 Found 303.04. 
 
 
(S)-N-tert-(Butoxycarbonyl)valine (6.2) 
The literature procedure130 was followed. Boc2O (14.41g, 66mmol) followed by sodium 
hydroxide (4.80g, 120mmol) were added to a solution of commercial L-valine (7.03g, 60mmol) in 
THF (120mL) and H2O (120mL). The mixture was stirred overnight and then the THF was 
removed in vacuum. The aqueous phase was washed with Et2O (2×100mL) and then acidified to 
pH3 with 1M HCl solution. The product was extracted into DCM (2×180mL), the combined 
organic phase was dried (MgSO4) and concentrated in vacuum to provide 
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(S)-N-tert-(butoxycarbonyl)valine 6.2 as a white foam (11.94g, 92%). The 1H NMR spectra 
matched that reported in the literature.132 
 
1H NMR (300 MHz, CDCl3) δ ppm 6.23 (br s, 1H), 5.03 (br m, 1H), 4.24 (m, 1H), 2.18 (m, 1H), 
1.42 (s, 9H), 0.97 (d, J = 6.8 Hz, 3H), 0.92 (d, J = 6.8 Hz, 3H). 
 
 
(S)-N-tert-(Butoxycarbonyl)valinamide (6.3) 
The literature procedure131 was followed. Anhydrous triethylamine (7.63mL, 55mmol) followed 
by ethyl chloroformate (5.26mL, 55mmol) were added to a solution of 
(S)-N-tert-(butoxycarbonyl)valine 6.2 (11.94g, 55mmol) in anhydrous THF (500mL) at 0oC under 
argon. The mixture was stirred in an ice bath for 1h and then concentrated aqueous ammonia 
(28%, 45mL) was added. The ice bath was removed and the mixture stirred for 1h. THF was 
removed to vacuum, the residue was diluted with water (60mL), and the product was extracted 
into EtOAc (3×200mL). The combined organic phase was washed with sat. NaHCO3 (1×250mL), 
10% citric acid (1×250mL), brine (1×250mL), dried (Na2SO4) and concentrated in vacuum to 
provide (S)-N-tert-(butoxycarbonyl)valinamide 6.3 as a white foam (9.14g, 77%). The 1H NMR 
spectra matched that reported in the literature.132 
 
1H NMR (300 MHz, CDCl3) δ ppm 6.04 (s, 1H), 5.66 (s, 1H), 5.06 (d, J = 8.7 Hz, 1H), 3.94 (m, 
1H), 2.12 (m, 1H), 1.39 (s, 9H), 0.94 (dd, J = 14.2, 6.8 Hz, 6H). 
 
LRMS (ESI): Calculated for C10H20N2O3Na
+
 239.28 Found 239.09. 
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(S)-N-tert-(Butoxycarbonyl)thiovalinamide (2.13) 
The literature procedure132 was followed. Under an argon atmosphere, Lawesson’s reagent 
(10.27g, 25.4mmol) was added to a solution of (S)-N-tert-(butoxycarbonyl)valinamide 6.3 (9.14g, 
42.3mmol) in anhydrous THF (200mL), and the mixture was stirred overnight at r.t. EtOAc 
(400mL) was added and the solution was washed with sat. NaHCO3, H2O and brine (1×40mL 
each). The organic phase was dried (Na2SO4) and concentrated in vacuum. Flash chromatography 
(silica gel, petroleum ether: ethyl acetate 2:1, Rf=0.6) provided 
(S)-N-tert-(butoxycarbonyl)thiovalinamide 2.13 as a white foam (8.76g, 89%). The 1H NMR and 
13C NMR spectra matched that reported in the literature.132 
 
1H NMR (400 MHz, CDCl3) δ ppm: 8.42 (s, 1H), 7.90 (s, 1H), 5.37 (s, 1H), 4.21 (m, 1H), 2.03 (m, 
1H), 1.42 (s, 9H), 0.95 (d, J = 6.2 Hz, 6H). 
 
13C NMR (100 MHz, CDCl3) δ ppm: 209.4, 171.2, 156.0, 80.2, 65.1, 60.4, 33.3, 28.3, 21.0, 19.5, 
18.3, 14.1, 1.0. 
 
LRMS (ESI): Calculated for C10H20N2O2SNa
+ 255.34 Found 255.06. 
 
 
Methyl 2-{1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}thiazole-5-carboxylate (2.23) 
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To a mixture of methyl trans-3-methoxyacrylate 2.21 (5.29mL, 42.4mmol) in water (21mL) and 
dioxane (21mL) at -10oC was added recrystallised NBS (8.33g, 46.6mmol). The reaction mixture 
was stirred at r.t. for 1h. After cooling the reaction to 0oC, 
(S)-N-tert-(butoxycarbonyl)thiophenylalaninamide 2.12 (11.90g, 42.42mmol) was added and the 
reaction allowed to warm to r.t. overnight. Then conc. NH4OH (8mL) was added dropwise and 
stirred for 10min. The resulting slurry was diluted with Et2O (200mL) and washed with water 
(3×400mL). The Et2O layer dried with Na2SO4 and concentrated in vacuum. Flash chromatography 
(silica gel, petroleum ether: ethyl acetate 4:1, Rf=0.61) provided methyl 
2-{1-[(tert-butoxycarbonly)amino]-2-phenylethyl}thiazole-5-carboxylate 2.23 as a white foam 
(5.7g, 37%, ee 82%). By-product 2.24 was obtained after purification (1.4g, 9%). 
 
 1H NMR (400 MHz, CDCl3) δ ppm 8.31 (s, 1H), 7.28 – 7.18 (m, 4H), 
7.06 (m, 1H), 5.21 (m, 1H), 3.86 (s, 3H), 3.27 (m, 2H), 1.39 (s, 9H). 
 
13C NMR (100 MHz, CDCl3) δ ppm 178.5, 171.1, 161.6, 148.4, 135.8, 
129.3, 128.6, 127.1, 80.4, 54.0, 52.4, 41.3, 28.2. 
 
HRMS (ESI): Calculated for C18H22N2O4S Na
+ 385.1300 Found 385.1192.  
 
[α]D
23 − 16.30 (𝐶 0.93, CHCl3) 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.29 – 7.25 (m, 2H), 7.22 – 7.13 
(m, 5H), 7.11 – 7.03 (m, 2H), 6.94 (m, 1H), 5.37 (m, 1H), 5.23 (s, 1H), 
3.27 (m, 4H), 1.41 (s, 9H), 1.39 (s, 9H). 
 
13C NMR (100 MHz, CDCl3) δ ppm 193.8, 175.7, 155.0, 154.9, 136.5, 
135.5, 129.5, 129.2, 128.7, 128.2, 127.2, 126.6, 80.6, 79.6, 53.7, 53.6, 52.8, 52.7, 41.1, 41.0, 29.6, 
28.2. 
 
HRMS (ESI): Calculated for C28H36N4O4S Na
+ 547.2457 Found 547.2340. 
 138 
 
 
Methyl 2-{1-[(tert-butoxycarbonyl)amino]-2-methylpropyl}thiazole-5-carboxylate (2.25) 
To a mixture of methyl trans-3-methoxyacrylate 2.21 (3.8mL, 35.3mmol) in water (18mL) and 
dioxane (18mL) at -10oC was added recrystallised NBS (6.9g, 38.8mmol). The reaction mixture 
was stirred at r.t. for 1h. After cooling the reaction to 0oC, 
(S)-N-tert-(butoxycarbonyl)thiovalinamide 2.13 (8.2g, 35.3mmol) was added and the reaction 
allowed to warm to r.t. overnight. Then conc. NH4OH (7mL) was added dropwise and stirred for 
10min. The resulting slurry was diluted with Et2O (180mL) and washed with water (3×360mL). The 
Et2O layer dried with Na2SO4 and concentrated in vacuum. Flash chromatography (silica gel, 
petroleum ether: ethyl acetate 4:1, Rf=0.45) provided methyl 
2-{1-[(tert-butoxycarbonyl)amino]-2-methylpropyl}thiazole-5-carboxylate 2.25 as a white foam 
(4.6g, 8%, ee 37%). By-product 2.26 was obtained after purification (1.3g, 34%). 
 
1H NMR (400 MHz, CDCl3) δ ppm 8.29 (s, 1H), 5.20 (d, J = 8.2 Hz, 
1H), 4.87 (dd, J = 8.4, 5.3 Hz, 1H), 3.87 (s, 3H), 2.35 (m, 1H), 1.43 (s, 
9H), 0.96 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 6.9 Hz, 3H). 
 
13C NMR (100 MHz, CDCl3) δ ppm 178.6, 161.8, 155.4, 148.5, 128.5, 80.3, 58.2, 52.4, 33.3, 28.3, 
19.2, 17.2. 
 
HRMS (ESI): Calculated for C14H22N2O4S Na
+ 337.1198 Found 337.1202. 
 
[α]D
23 − 9.35 (𝐶 0.93, CHCl3) 
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1H NMR (400 MHz, CDCl3) δ ppm 5.41 (d, J = 9.0 Hz, 1H), 5.17 (d, J 
= 8.3 Hz, 1H), 5.02 (m, 2H), 2.09 (m, 1H), 1.97 (m, 1H), 1.43 (s, 18H), 
0.97 (d, J = 6.8 Hz, 3H), 0.87 (d, J = 6.9 Hz, 6H), 0.83 (d, J = 6.8 Hz, 
3H). 
 
13C NMR (100 MHz, CDCl3) δ ppm 193.4, 176.2, 155.5, 155.3, 80.5, 79.5, 40.1, 39.5, 28.3, 28.3, 
24.9, 24.6, 15.4, 15.4, 11.6. 
 
HRMS (ESI): Calculated for C20H36N4O4S Na
+ 451.2355 Found 451.2364. 
 
 
N-Phenylhydroxylamine (2.33) 
The literature procedure138 was followed. Ammonium chloride (5.35g, 0.1mol) was dissolved in 
twice-distilled H2O (200mL). Nitrobenzene (10.3mL, 0.1mol) was added to the solution and the 
mixture heated with stirring until the temperature reached 60oC. Zn dust (13.08g, 0.2mol) was 
added over 20min. As the reaction proceeded, the temperature rose to 70-80oC (zinc dust addition 
must be to keep the temperature under 80oC). After the Zn addition was completed, the mixture 
was stirred an additional 15-20min or until the temperature returned to 60-65oC. While still hot, 
the solution was filtered with suction to remove the zinc oxide. The solid was washed with hot 
water (300-400mL, 90oC) to remove as much hydroxylamine from the zinc oxide as possible. The 
filtrate was saturated with NaCl and placed in an ice-salt bath. Crystals were formed within 1h 
and isolated by filtration and re-dissolved in ether to remove NaCl. The ether was removed and 
dried in vacuum to give phenylhydroxylamine 2.33 as white needles. The product was used 
without further purification immediately after preparation (4.19g, 42%). The 1H NMR spectra 
matched that reported in the literature.138 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.31 – 7.24 (m, 2H), 7.03 – 6.94 (m, 3H). 
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Ethyl 5-oxo-2-phenyl-2,5-dihydroisoxazole-4-carboxylate (2.35) 
Following the reported procedure140, diethyl ethoxymethylenemalonate (2.40g, 11.00mmol) and 
freshly prepared N-phenylhydroxylamine 2.33 (1.20g, 11.00mmol) were refluxed in ethanol 
(50mL) in the absence of light. After 24h, the mixture was partially cooled for 30min. Et2O 
(50mL) was then added to the still warm solution, which was cooled to r.t. over 2h. The product 
was collected by filtration, but a further crop was obtained on partial evaporation of the solvent. 
The product was recrystallised from ethanol/ether to afford white needles (0.879g, 25%). The 1H 
NMR spectra matched that reported in the literature.138 
 
1H NMR (500 MHz, CDCl3) δ ppm 8.75 (s, 1H), 7.53 – 7.43 (m, 2H), 7.39 – 7.31 (m, 3H), 4.34 
(q, J = 7.2 Hz, 2H), 1.35 (t, J = 7.1 Hz, 3H).  
 
 
Ethyl 2-{1-[(tert-butoxycarbonyl)amino]-2-methylpropyl}thiazole-5-carboxylate (2.16) 
A solution of ethyl 5-oxo-2-phenyl-2,5-dihydroisoxazole-4-carboxylate 2.35 (0.650g, 2.80mmol) 
and (S)-N-tert-(butoxycarbonyl)thiovalinamide 2.13 (1.50g, 6.44mmol) in anhydrous CH3CN 
(700mL), and TFA (0.35mL), was degassed and irradiated for 2h under nitrogen at 300nm through 
pyrex (450 Watt Hanovia Mercury Vapour Lamp). The solvent was removed, replaced with Et2O 
(140mL). The solution was washed with 1M HCl (2×140mL), Na2CO3 solution (2×140mL) and 
brine (2×140mL). Flash chromatography (silica gel, petroleum ether: ethyl acetate 4:1, Rf=0.49) 
gave ethyl 2-[1-(tert-butoxycarbonyl)amino)-2-methylpropyl]thiazole-5-carboxylate 2.16 (0.542g, 
62%, ee 33%). 
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1H NMR (400 MHz, CDCl3) δ ppm 8.25 (s, 1H), 5.27 (br s, 1H), 4.84 (br m, 1H), 4.30 (q, J = 7.1 
Hz, 2H), 2.31 (m, 1H), 1.40 (s, 9H), 1.31 (t, J = 7.1 Hz, 3H), 0.93 (d, J = 6.8 Hz, 3H), 0.86 (d, J = 
6.9 Hz, 3H). 
 
13C NMR (100 MHz, CDCl3) δ ppm 178.3, 161.3, 155.3, 148.2, 128.9, 80.1, 77.3, 77.0, 76.7, 61.5, 
58.1, 33.2, 28.2, 19.2, 17.2, 14.2. 
 
HRMS (ESI): Calculated for C15H24N2O4SNa
+ 351.1349 Found 351.1340. 
 
[α]D
23 − 4.94 (𝐶 2.08, CHCl3) 
 
 
Ethyl 2-{1-[(tert-butoxycarbonyl)amino]-2-phenylethyl}thiazole-5-carboxylate (2.15) 
A solution of ethyl 5-oxo-2-phenyl-2,5-dihydroisoxazole-4-carboxylate 2.35 (0.7g, 3mmol) and 
(S)-N-tert-(butoxycarbonyl)thiophenylalaninamide 2.12 (1.9g, 6.9mmol) in anhydrous CH3CN 
(700mL), and TFA (0.35mL), was degassed and irradiated for 2h under nitrogen at 300nm through 
pyrex (450 Watt Hanovia Mercury Vapour Lamp). The solvent was removed, replaced with Et2O 
(140mL). The solution was washed with 1M HCl (2×140mL), Na2CO3 solution (2×140mL) and 
brine (2×140mL). Flash chromatography (silica gel, petroleum ether: ethyl acetate 4:1, Rf=0.41) 
gave ethyl 2-[1-(tert-butoxycarbonyl)amino)-2- phenylethyl]thiazole-5-carboxylate 2.15 (0.647g, 
60%, ee 25%). 
 
1H NMR (400 MHz, CDCl3) δ ppm 8.31 (s, 1H), 7.28 – 7.18 (m, 3H), 
7.09 – 7.02 (m, 2H), 5.26 (br t, J = 5.6 Hz, 1H), 5.14 (br d, J = 7.0 Hz, 
1H), 4.32 (q, J = 7.1 Hz, 2H), 3.36 –3.16 (m, 2H), 1.39 (s, 9H), 1.34 (t, 
J = 7.1 Hz, 3H). 
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13C NMR (100 MHz, CDCl3) δ ppm 178.2, 161.3, 154.9, 148.3, 135.9, 129.4, 128.6, 127.1, 80.4, 
61.6, 54.0, 41.3, 28.2, 14.2. 
 
HRMS (ESI): Calculated for C19H24N2O4SNa
+ 399.1354 Found 399.1348. 
 
[α]D
23 − 4.31 (𝐶 0.58, CHCl3) 
 
 
(1S)-Methyl 2-[(S)-2-amino-3-phenylpropanoyl]cyclopentanecarboxylate (dipeptide) (2.45) 
SOCl2 (1.26mL, 17.36mmol) was added dropwise to a solution of L-proline (1.00g, 8.68mmol) in 
anhydrous MeOH (20mL) at 0℃. The mixture was refluxed under argon (balloon) for 1h and then 
concentrated in vacuum to provide the crude product L-proline methyl ester hydrochloride 2.44 as 
pale yellow oil.  
 
(S)-N-tert-(Butoxycarbonyl)phenylalanine 2.10 (0.801g, 0.302mmol), L-proline methyl ester 
hydrochloride 2.44 (0.050g, 0.302mmol), BOP (0.147g, 0.332mmol), NaHCO3 (0.147g) were 
mixed and dried for 2h under high vacuum. Then anhydrous DMF (2mL) was added and the 
mixture was sonicated for 2h. The reaction was diluted with H2O (6mL) and extracted with 
EtOAc (3×2mL) and dried over Na2SO4 overnight. Solvent evaporation and flash chromatography 
(silica gel, petroleum ether: ethyl acetate 1:1, Rf=0.61) gave titled compound 2.45 as a white 
powder (0.044g, 38%). The 1H NMR and 13C NMR spectra matched that reported in the 
literature.166 
 
1H NMR (400 MHz, Toluene-d8) δ ppm 7.29 (d, J = 7.3 Hz, 2H), 7.16 (t, J = 7.6 Hz, 2H), 7.06 (m, 
1H), 5.44 (d, J = 8.5 Hz, 1H), 4.69 (dd, J = 14.6, 7.2 Hz, 1H), 4.34 (t, J = 6.6 Hz, 1H), 3.35 (s, 
3H), 3.11 (dd, J = 13.6, 7.2 Hz, 1H), 3.00 – 2.82 (m, 2H), 2.70 (m, 1H), 1.47 – 1.39 (m, 2H), 1.38 
(s, 9H), 1.32 (m, 1H), 1.08 (m, 1H). 
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13C NMR (100MHz, Toluene-d8) δ ppm 172.2, 170.4 155.3, 130.3, 128.5, 126.8, 79.0, 59.0, 53.7, 
51.4, 46.5, 39.60, 28.9, 28.4, 24.8. 
 
1H NMR (400 MHz, CDCl3) δ ppm 7.33 – 7.11 (m, 5H), 5.23 (d, J = 8.7 Hz, 1H), 4.61 (dd, J = 
15.5, 6.9 Hz, 1H), 4.46 (dd, J = 8.3, 4.1 Hz, 1H), 3.70 (s, 3H), 3.53 (m, 1H), 3.14 (m, 1H), 3.05 (dd, 
J = 13.7, 6.9 Hz, 1H), 2.87 (dd, J = 13.9, 6.3 Hz, 1H), 2.12 (m, 1H), 2.01 – 1.76 (m, 3H), 1.34 (s, 
9H). 
 
13C NMR (100MHz, CDCl3) δ ppm 172.2, 171.8, 170.6, 155.1, 154.6, 136.5, 136.3, 129.7, 129.3, 
128.5, 128.3, 126.9, 126.7, 79.5, 79.4, 58.8, 53.7, 53.2, 52.6, 52.1, 46.7, 45.9, 41.1, 39.1, 30.5, 
28.9, 28.2, 24.8, 22.1. 
 
LRMS (ESI): Calculated for C20H28N2O5Na
+ 399.45 Found 399.02. 
 
 
 
(1S)-2-((S)-2-(2-((S)-1-((tert-Butoxycarbonyl)amino)-2-phenylethyl)thiazole-5-carboxamido)-
3-phenylpropanoyl)cyclopentanecarboxylic acid (The tetrapeptide, Block B) (2.49) 
N-Butoxycarbonlyamino-L-phenylalanine-L-proline methyl ester 2.45 (0.262g, 0.7mmol) was 
dissolved in MeOH (2mL) and SOCl2 (10μL) was added under stirring. The mixture was stirred at 
r.t. for 5h, until the reaction was completed, evaporated (45oC) and dried at reduce pressure (10 
Torr) to give crude amine hydrochloride. The residue was suspended in DCM (2 mL) and the 
solution evaporated at reduced pressure, this operation was repeated two times and the pale 
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yellow oily residue was then dried under high vacuum for 1h to provide 
N-butoxycarbonlyamino-L-phenylalanine-L-proline methyl ester hydrochloride. 
 
NaOH solution (1M) was added dropwise to a solution of methyl 
2-[1-(tert-butoxycarbonlyamino)-2-phenylethyl]thiazole-5-carboxylate 2.15 (1.00g, 2.76mmol) in 
THF (20mL), MeOH (20mL), and H2O (10mL), and the mixture was stirred at r.t. for 1.5h. The 
THF, and MeOH, were removed in vacuum and the residue was diluted with H2O (40mL). The 
aqueous phase was washed with Et2O (4×40mL) and then acidified to pH 3 with 10% citric acid 
solution. The product was extracted into EtOAc (3×60mL), and the combined organic phase was 
washed with H2O, and brine (1×60mL each). The combined organic phase was dried (Na2SO4) 
and concentrated in vacuum to provide crude 
2-{1-[(tert-butoxycarbonly)amino]-2-phenylethyl}thiazole-5-carboxylic acid as a white solid. 
 
Method one: 2-[1-(tert-Butoxycarbonlyamino)-2-phenylethyl]thiazole-5-carboxylic acid 
(0.579g,1.66mmol), N-butoxycarbonlyamino-L-phenylalanine-L-proline methyl ester 
hydrochloride (0.588g, 1.66mmol), BOP (0.808g, 1.83mmol), NaHCO3 (0.808g) were mixed and 
dried for 2h under high vacuum. Then anhydrous DMF (11mL) was added and the mixture was 
sonicated for 2h. The reaction was diluted with H2O (33mL), extracted with EtOAc (3×10mL), 
and dried over Na2SO4 overnight. Solvent evaporation and flash chromatography (silica gel, 
petroleum ether: ethyl acetate 1:3, Rf=0.56) gave 2.49 as a white foam (0.829g, 89%). 
 
Method two: 2-[1-(tert-Butoxycarbonlyamino)-2-phenylethyl]thiazole-5-carboxylic acid (0.337g, 
0.97mmol), N-butoxycarbonlyamino-L-phenylalanine-L-proline methyl ester hydrochloride 
(0.361g, 1.02mmol) were dissolved in anhydrous DMF (12mL) under argon. The solution was 
cooled down to 0oC, and then TMP (0.4mL, 3mmol) was added to the solution dropwise followed 
by COMU (0.430g, 1mmol). The reaction was then stirred at 0oC for 1 h, the ice bath was 
removed and the reaction was allowed to be warmed up to r.t. with stirring over 2 hrs. After the 
reaction was complete (monitored by TLC), the reaction was diluted with EtOAc, and washed 
with 1M HCl solution (2×40mL), saturated NaHCO3 solution (2×40mL), brine solution (40mL), 
then dried over MgSO4, filtered and evaporated. Flash chromatography (silica gel, petroleum 
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ether: EtOAc 1:3, Rf=0.56) gave the pure Block B 2.49 as a white foam (0.575g, 95%). 
 
1H NMR (400 MHz, Toluene-d8) δ ppm 8.94 (br s, 1H),  
8.22 (s, 1H), 7.50 – 7.38 (m, 2H), 7.27 – 7.18 (m, 3H), 
7.09 – 7.03 (m, 5H), 5.79 (br s, 1H), 5.43 (m, 1H), 5.10 (q, 
J = 7.2 Hz, 1H), 4.59 (dd, J = 8.2, 4.5 Hz, 1H), 3.51 (m, 
1H), 3.33 (s, 3H), 3.26 (d, J = 6.9 Hz, 3H), 3.09 – 2.90 (m, 2H), 1.64 – 1.41 (m, 3H), 1.34 (s, 9H), 
0.94 (br m, 1H). 
 
13C NMR (100MHz, Toluene-d8) δ ppm 172.1, 160.7, 159.9, 155.4, 143.5, 130.0, 129.7, 127.0, 
126.8, 79.4, 59.4, 54.8, 54.2, 51.7, 47.0, 42.6, 37.6, 28.9, 28.4, 24.9. 
 
1H NMR (500 MHz, CDCl3) δ ppm 8.81 (br s, 1H), 7.99 (s, 1H), 7.30 – 7.01 (m, 10H), 5.75 (br s, 
1H), 5.17 (br m, 1H), 4.95 (m, 1H), 4.64 (m, 1H), 3.82 (m, 1H), 3.52 (s, 3H), 3.47 (br m, 1H), 3.24 
(m, 1H), 3.16 – 2.89 (m, 3H), 2.21 (m, 1H), 1.98 – 1.88 (m, 3H), 1.32 (s, 9H). 
 
13C NMR (100MHz, CDCl3) δ ppm 176.0, 172.0, 171.6, 160.3, 159.3, 154.9, 143.3, 143.0, 136.8, 
136.4, 134.2, 129.2, 129.1, 128.2, 126.6, 126.6, 79.7, 58.9, 54.0, 53.6, 52.0, 46.8, 42.1, 38.3, 36.8, 
28.7, 28.1, 24.7. 
 
HRMS (ESI): Calculated for C32H38N4O6SNa
+ 629.2404 Found 629.2398. 
 
[α]D
23 − 67.77 (𝐶 0.76, CHCl3) 
 
1H NMR (400 MHz, Toluene-d8) δ ppm 8.47 (d, J = 7.1 
Hz, 1H), 8.16 (s, 1H), 7.49 – 7.35 (m, 2H), 7.27 – 7.17 (m, 
3H), 7.08 – 7.03 (m, 5H), 5.35 (br d, J = 7.8 Hz, 1H), 5.28 
(m, 1H), 5.11 (m, 1H), 4.54 (m, 1H), 3.90 – 3.38 (m, 2H), 
3.34 (s, 3H), 3.32 – 3.16 (m, 2H), 3.14 – 2.91 (m, 2H), 1.65 (m, 1H), 1.57 – 1.41 (m, 3H), 1.31 (s, 
9H). 
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13C NMR (100MHz, Toluene-d8) δ ppm 176.7, 172.1, 160.6, 155.1, 144.2, 130.1, 129.8, 127.0, 
126.7, 79.4, 59.4, 54.7, 53.8, 53.7, 51.6, 47.0, 41.1, 41.0, 40.9, 38.0, 30.3, 29.0, 28.3, 24.9. 
 
1H NMR (500 MHz, CDCl3) δ ppm 8.00 (s, 1H), 7.38 – 7.00 (m, 10H), 5.36 (br s, 1H), 5.16 (br 
m, 1H), 4.98 (dd, J = 14.2, 7.4 Hz, 1H), 4.56 (m, 1H), 3.76 (m, 1H), 3.63 (s, 3H), 3.44 – 3.25 (m, 
2H), 3.24 – 2.87 (m, 3H), 2.20 (m, 1H), 2.01 – 1.90 (m, 3H), 1.32 (s, 9H). 
 
13C NMR (100MHz, CDCl3) δ ppm 176.4, 172.1, 170.8, 170.8, 160.2, 159.3, 154.9, 143.8, 136.4, 
133.6, 129.5, 129.3, 128.4, 128.4, 126.8, 80.0, 59.1, 53.9, 53.0, 52.1, 47.0, 40.9, 37.7, 28.9, 28.1, 
24.8. 
 
HRMS (ESI): Calculated for C32H38N4O6SNa
+ 629.2404 Found 629.2390. 
 
[α]D
23 − 13.31 (𝐶 0.77, CHCl3) 
 
 
Ethyl 2-[(S)-1-((S)-2-amino-3-methylbutanamido)-2-methylpropyl]thiazole-5-carboxylate 
(The tripeptide, Block A) (2.53) 
L-allo-Threonine (244 mg, 2.05 mmol), H2O (38 mL) and NaHCO3 (275 mg, 3.12 mmol) were 
placed in a round bottom flask and stirred for 10 min giving a clear solution. MeOH (38 mL) and 
Boc2O (467 mg, 2.68 mmol) were added subsequently and the mixture was stirred overnight at r.t. 
The reaction mixture was evaporated to dryness, dissolved in EtOH (10 mL), and passed through 
a pad of silica (5 mL, 2cm column) with EtOH. The ethanolic solution was evaporated and the 
residue was dried under high vacuum overnight to give Boc-L-allo-threonine as a white powder. 
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A mixture of ethyl 2-[1-(tert-butoxycarbonlyamino)-2-methylpropyl]thiazole-5-carboxylate 2.16 
(0.40g, 1.22mmol), TFA (2.5mL) and DCM (2.5mL) was stirred for 1h, progress of the reaction 
was monitored by TLC, and on completion the solvents were evaporated to dryness. The residue 
was dissolved in DCM (2.5mL) and the solution evaporated at reduced pressure, this operation 
was repeated twice, and then the residue was dried at high vacuum for 1h. Flash chromatography 
(silica gel, EtOAc: MeOH 10:1, Rf=0.7) provided ethyl 
2-[1-(tert-amino)-2-methylpropyl]thiazole-5-carboxylate TFA salt as a pale yellow oil. 
 
Method one: Ethyl 2-[1-(tert-amino)-2-methylpropyl]thiazole-5-carboxylate TFA salt (0.175g, 
0.792mmol), BOC-L-allo-threonine (0.271g, 0.792mmol), BOP (0.387g, 0.871mmol), NaHCO3 
(0.387g) were mixed, and then dried for 2h under high vacuum. Anhydrous DMF (5.2mL) was 
then added, and the mixture sonicated for 2h. On completion the reaction was diluted with H2O 
(16mL), extracted with EtOAc (3×5mL), and dried over Na2SO4 overnight. Solvent evaporation 
and flash chromatography (silica gel, petroleum ether: EtOAc 1:3, Rf=0.56) gave 2.53 as a white 
foam (0.142g, 42%). 
 
Method two: Ethyl 2-[1-(tert-amino)-2-methylpropyl]thiazole-5-carboxylate TFA salt (0.297g, 
1.3mmol) and BOC-L-allo-threonine (0.285g, 1.3mmol) were dissolved in anhydrous DMF 
(12mL) under argon. The solution was cooled to 0oC, and then TMP (0.52mL, 3.9mmol) was 
added dropwise followed by COMU (0.668g, 1.56mmol). The reaction was then stirred at 0oC for 
1 h, and then allowed to warm up to r.t. After the reaction was complete (monitored by TLC, 2 
hrs), the reaction was diluted with EtOAc and washed with 1M HCl solution (2×40mL), saturated 
NaHCO3 solution (2×40mL), and brine solution (40mL), dried over MgSO4, filtered and 
evaporated. Flash chromatography (silica gel, petroleum ether: EtOAc 1:2, Rf=0.61) gave the pure 
Block A 2.53 as a white foam (0.385g, 69%). 
 
1H NMR (400 MHz, CDCl3) δ ppm 8.26 (s, 1H), 7.06 (br d, J = 8.0 
Hz, 1H), 5.52 (br d, J = 7.7 Hz, 1H), 5.20 (dd, J = 8.9, 5.1 Hz, 1H), 
4.33 (q, J = 7.1 Hz, 2H), 4.27 (d, J = 6.8 Hz, 1H), 3.99 (m, 1H), 
3.85 (m, 1H), 2.36 (m, 1H), 1.43 (s, 9H), 1.35 (t, J = 7.2 Hz, 3H), 
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1.28 (d, J = 6.4 Hz, 3H), 0.98 (d, J = 6.8 Hz, 3H), 0.90 (d, J = 6.9 Hz, 1H). 
 
13C NMR (100MHz, CDCl3) δ ppm 176.8, 171.9, 161.0, 156.1, 147.8, 80.5, 69.1, 61.7, 58.3, 56.8, 
33.3, 28.3, 20.1, 19.3, 17.0, 14.3. 
 
HRMS (ESI): Calculated for C19H31N3O6SNa
+ 452.1826 Found 452.1821. 
 
[α]D
23 − 71.18 (𝐶 0.80, CHCl3) 
 
1H NMR (400 MHz, CDCl3) δ ppm 8.25 (s, 1H), 7.34 (br d, J = 4.3 
Hz, 1H), 5.59 (d, J = 7.5 Hz, 1H), 5.15 (dd, J = 8.7, 5.6 Hz, 1H), 
4.32 (q, J = 7.1 Hz, 2H), 4.05 (br m, 1H), 3.96 (m, 1H), 2.34 (m, 1H), 
1.41 (s, 9H), 1.34 (t, J = 7.1 Hz, 3H), 1.28 (d, J = 6.4 Hz, 3H), 0.96 
(d, J = 6.8 Hz, 3H), 0.91 (d, J = 6.8 Hz, 3H). 
 
13C NMR (100MHz, CDCl3) δ ppm 176.7, 171.4, 161.1, 156.3, 156.2, 147.9, 129.3, 80.7, 68.8, 
61.7, 58.4, 56.7, 33.0, 28.3, 19.9, 19.3, 17.4, 14.3. 
 
HRMS (ESI): Calculated for C19H31N3O6SNa
+ 452.1826 Found 452.1820. 
 
[α]D
23 − 20.05 (𝐶 1.88, CHCl3) 
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The linear peptide (2.61a) 
Tetrapeptide (Block B) 2.49b (0.303g, 0.5mmol), THF (4mL), MeOH (4mL) and 1M NaOH 
(1mL) were added together and stirred for 5 hrs. On reaction completion (TLC, 17 hrs) of the 
reaction the solvents were evaporated and the residue was dissolved in EtOAc (10mL), 
neutralised with 1% HCl (about 2mL), diluted with brine (5 mL), separated and extracted again 
with EtOAc (5mL). The organic layer was dried over Na2SO4. The solvent was evaporated giving 
a pale yellow solid residue as the tetrapeptide (Block B) acid. 
 
The tripeptide (Block A) 2.53a (0.160mg, 0.373mmol) was dissolved in MeOH (1.5mL) and 
SOCl2 (5 drops) was added with stirring. The mixture was stirred at r.t. for 5-30 hrs, until the 
reaction was complete (monitored by TLC). Evaporation at reduce pressure gave the crude amine 
hydrochloride. The residue was suspended in DCM (2 mL), and the solution was evaporated 
under reduced pressure. This operation was repeated twice before the residue was dried under 
high vacuum for 1 h to give the tripeptide (Block A) amine hydrochloride as pale yellow oil. 
 
Method one: The above tripeptide (Block A) amine hydrochloride (0.095g, 0.289mmol) and the 
above tetrapeptide (Block B) acid (0.171g, 0.289mmol), BOP (0.141g, 0.318mmol), NaHCO3 
(0.141g) were mixed and dried for 2h under high vacuum. Anhydrous DMF (2mL) was then 
added, and the mixture was sonicated for 2h. The reaction was diluted with H2O (8mL), extracted 
with EtOAc (3×3mL) and dried over Na2SO4 overnight. Solvent evaporation and flash 
chromatography gave the linear peptide 2.61a as a white foam (0.123g, 47%). 
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Method two: The above tripeptide (Block A) amine hydrochloride (0.329g, 0.36mmol) and the 
above tetrapeptide (Block B) acid (0.213g, 0.36mmol) were dissolved in anhydrous DMF (4mL) 
under argon. The solution was cooled to 0oC, and then TMP (0.143mL, 1.08mmol) was added to 
the solution dropwise followed by COMU (0.173g, 0.4mmol). The reaction was then stirred at 
0oC for 1 h, and then allowed to warm up to r.t. After the reaction was complete (monitored by 
TLC, 2 hrs), it was diluted with EtOAc, washed with 1M HCl solution (2×13mL), saturated 
NaHCO3 solution (2×13mL), and brine solution (13mL), and then dried over MgSO4, filtered and 
evaporated. Flash chromatography (silica gel, petroleum ether: EtOAc 1:3, Rf=0.55) gave the pure 
linear peptide 2.61a as a white foam (0.235g, 66%). 
 
1H NMR (400 MHz, CDCl3) δ ppm 8.22 (s, 1H), 8.07 (s, 1H), 7.67 (br m, 1H), 7.42 (br m, 1H), 
7.23 – 7.15 (m, 8H), 7.10 – 7.01 (m, 2H), 5.21 (dd, J = 8.7, 5.1 Hz, 2H), 5.02 (d, J = 7.7 Hz, 1H), 
4.73 (br m, 1H), 4.48 – 4.40 (m, 2H), 4.30 (q, J = 7.1 Hz, 2H), 3.95 (m, 1H), 3.66 (m, 1H), 3.30 – 
3.16 (m, 3H), 3.08 (dd, J = 13.6, 6.9 Hz, 1H), 2.98 (dd, J = 13.6, 6.9 Hz, 1H), 2.34 (m, 1H), 2.00 – 
1.83 (m, 4H), 1.36 (s, 9H), 1.32 (t, J = 7.1 Hz, 3H), 1.27 (d, J = 6.4 Hz, 3H), 0.97 (d, J = 6.8 Hz, 
3H), 0.91 (d, J = 6.8 Hz, 3H). 
 
13C NMR (100MHz, CDCl3) δ ppm 176.7, 171.8, 171.1, 171.1, 161.0, 160.1, 147.5, 143.9, 135.9, 
133.6, 129.7, 129.4, 129.3, 128.6, 127.1, 127.0, 80.3, 68.8, 61.7, 58.1, 57.1, 53.9, 52.7, 47.5, 41.3, 
38.3, 33.3, 28.2, 25.1, 21.0, 20.0, 19.3, 17.2, 14.2. 
 
HRMS (ESI): Calculated for C45H57N7O9S2Na
+ 926.3551 Found 926.3551. 
 
 
Cyclic peptide (2.63a) 
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The linear peptide 2.61a (0.064g, 0.071 mmol), THF (0.57mL), MeOH (0.57mL) and 1M NaOH 
(0.14mL) were added together and stirred for about 5 hrs. On reaction completion (TLC, 2 hrs) 
the solvents were evaporated, and the residue was suspended in brine (1.2mL), neutralised with 
1%HCl (1mL) and extracted with EtOAc (3×1.7mL). The organic layer was dried over Na2SO4, 
and the solvent evaporated to give crude linear peptide acid as a pale yellow solid, which was 
used without further purification. 
 
A 50% TFA solution in DCM (0.6mL) was added to the linear peptide acid (37mg, 0.042mmol) 
above at 0oC. The mixture was warmed to r.t. and stirred at r.t. until the reaction was complete 
(TLC, 2 hrs). Evaporation at reduce pressure gave crude amine TFA salt. The residue was 
suspended in DCM (2mL) and evaporated at reduced pressure. This operation was repeated twice 
and the residue further dried under high vacuum for 1 h, giving a pale yellow oily residue, which 
used without further purification. 
 
Method one: The deprotected linear peptide acid (0.069g, 0.085mmol), BOP (0.042g, 0.094mmol), 
and NaHCO3 (0.042g) were dried for 2 hrs under high vacuum. Anhydrous DMF (32.3mL) was 
then added and the mixture was stirred at r.t. A second equal portion of BOP/NaHCO3 was added 
after 16 hrs and stirring continued for an additional 48 hrs. The reaction was quenched with H2O 
(200mL) and extracted with EtOAc (4×100mL), dried overnight with Na2SO4. Solvent 
evaporation and flash chromatography (silica gel, chloroform: MeOH 9:1, Rf=0.32) gave cyclic 
peptide 2.63a (0.005g, 8% over three steps). 
 
Method two: The deprotected linear peptide acid (0.1g, 0.129mmol) was dissolved in anhydrous 
DMF (50mL) under argon. The solution was cooled to 0oC, and TMP (0.051mL, 0.39mmol) 
added to the solution dropwise, followed by COMU (0.06g, 0.14mmol). The reaction was then 
stirred at 0oC for 1 h, after which the reaction was allowed to warm up to r.t. overnight. On 
completion (monitored by TLC, 72 hrs), the reaction was diluted with EtOAc (500mL) and 
washed with 1M HCl solution (2×120mL), saturated NaHCO3 solution (2×120mL), and brine 
solution (120mL), and then dried over MgSO4, filtered and evaporated. Flash chromatography 
(silica gel, petroleum ether: EtOAc 1:10, Rf=0.3) gave the pure cyclic peptide 2.63a as a white 
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foam (0.015g, 30% over three steps). 
 
1H NMR (400 MHz, CDCl3) δ ppm 8.47 (d, J = 9.0 Hz, 1H), 8.26 (s, 1H), 8.12 (d, J = 9.3 Hz, 1H), 
8.08 (s, 1H), 7.37 – 7.18 (m, 5H), 7.17 – 6.98 (m, 5H), 5.24 (m, 1H), 4.84 (m, 1H), 4.40 (m, 1H), 
4.31 (m, 1H), 4.13 (m, 1H), 3.90 (br m, 1H), 3.59-3.43 (m, 2H), 3.37 (m, 1H), 3.26 (m, 1H), 3.16 – 
2.99 (m, 2H), 2.95 (m, 1H), 2.34 (m, 1H), 2.09 – 1.88 (m, 3H), 1.19 (d, J = 6.0 Hz, 3H), 0.97 (d, J = 
6.8 Hz, 3H), 0.95 (d, J = 6.8 Hz, 3H). 
 
13C NMR (125 MHz, CDCl3) δ ppm 176.6, 174.0, 173.6, 171.2, 170.1, 169.6, 168.4, 160.7, 145.0, 
142.2, 141.7, 136.7, 134.7, 134.4, 132.3, 129.7, 129.4, 129.2, 129.1, 129.0, 128.8, 66.8, 64.8, 62.8, 
60.8, 59.2, 57.7, 57.5, 57.1, 55.3, 53.3, 52.8, 47.8, 46.8, 42.6, 39.3, 38.1, 37.9, 33.9, 32.7, 31.2, 29.7, 
27.7, 25.5, 22.2, 21.3, 19.3, 19.1, 18.6, 18.3. 
 
HRMS (ESI): Calculated for C38H43N7O6S2Na
+ 780.2608 Found 780.2614. 
 
 
HI-lissoclinamide 5 (1.143) 
Cyclic peptide 2.63 (0.001g, 0.0013mmol), dried under high vacuum, was dissolved in anhydrous 
DCM (0.1mL). The solution was cooled to -17oC (salt-ice bath) followed by addition of 
Deoxo-Fluor (one drop from a 0.025mL syringe, 0.002mmol). After stirring for 10min, the 
reaction was kept in the freezer (-24oC) for two days. The reaction was quenched by addition of 
NaHCO3 solution at -17
oC (salt-ice bath). The salt-ice bath was then removed and the reaction 
was allowed to warm up to r.t. with addition of one more drop of saturated NaHCO3 solution. The 
mixture was then diluted with EtOAc and dried over MgSO4, filtered and evaporated. The crude 
product was purified by chiral HPLC (hexane: isopropyl alcohol 1:4, Rf=0.58, using IA column 
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with isocratic conditions of 45% isopropanol in hexane over 60 min.10uL of a 2mg/mL solution) 
to give enantiomeric pure HI-lissoclinamide 5 1.143 as a white solid (0.87mg, 90%). 
 
1H NMR (900 MHz, CDCl3) δ ppm 8.15 (s, 1H), 8.00 (s, 1H), 7.37 – 
7.24 (m, 10H), 7.19 (br d, J = 7.3 Hz, 1H), 6.84 (br d, J = 10.1 Hz, 
1H), 6.70 (br d, J = 7.5 Hz, 1H), 6.18 (br d, J = 7.4 Hz, 1H), 5.97 (br 
s, 1H), 5.45 (m, 1H), 5.08 (dd, J = 10.1, 5.0 Hz, 1H), 4.72 (m, 1H), 
4.64 (m, 1H), 3.99 (d, J = 9.8 Hz, 1H), 3.53 (m, 1H), 3.47 (m, 1H), 
3.41 (dd, J = 14.1, 6.4 Hz, 1H), 3.28 (dd, J = 14.2, 7.7 Hz, 1H), 3.24 
(m, 1H), 3.20 (m, 1H), 2.93 (m, 1H), 2.58 (m, 1H), 1.90 (m, 1H), 
1.70 (m, 1H), 1.47 (m, 3H), 0.91 (d, J = 6.8 Hz, 3H), 0.77 (d, J = 6.8 Hz, 3H). 
 
13C NMR (226 MHz, CDCl3) δ ppm 175.5, 175.0, 170.7, 170.4, 167.4, 159.1, 145.1, 136.2, 135.0, 
133.6, 129.6, 129.3, 129.0, 128.7, 128.5, 127.6, 127.3, 81.8, 74.8, 55.4, 54.9, 54.6, 46.9, 46.8, 45.6, 
40.6, 37.7, 37.8, 30.2, 29.7, 22.1, 21.4, 19.7, 16.8. 
 
HRMS (ESI): Calculated for C38H41N7O5S2Na
+ 762.2503 Found 762.2508.  
 
[α]D
23 − 17.42 (𝐶 0.21, CHCl3) 
 
1H NMR (900 MHz, CDCl3) δ ppm 8.10 (s, 1H), 8.07 (s, 1H), 7.34 – 
7.25 (m, 10H), 7.10 (br d, J = 7.3 Hz, 1H), 6.87 (br d, J = 8.3 Hz, 1H), 
6.75 (br d, J = 9.9 Hz, 1H), 6.16 (d, J = 7.2 Hz, 1H), 5.17 (dq J = 13.6, 
6.8 Hz, 1H), 5.08 (dd, J = 9.8, 6.3 Hz, 1H), 4.82 (m, 1H), 4.61 (m, 
1H), 4.05 (d, J = 10.0 Hz, 1H), 3.61 (d, J = 8.3 Hz, 1H), 3.58 (m, 1H), 
3.31 (dd, J = 14.1, 7.2 Hz, 1H), 3.25 (dd, J = 14.0, 6.5 Hz, 1H), 3.20 
(m, 1H), 3.08 – 3.05 (m, 2H), 2.28 (m, 1H), 1.89 (m, 1H), 1.62 (d, J = 
6.1 Hz, 3H), 0.85 (d, J = 6.7 Hz, 3H), 0.73 (d, J = 6.7 Hz, 3H). 
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13C NMR (226 MHz, CDCl3) δ ppm 176.0, 175.9, 175.3, 175.2, 171.1, 171.0, 170.4, 170.3, 167.5, 
167.4, 163.9, 163.8, 159.6, 159.5, 148.0, 147.9, 142.4, 142.3, 136.3, 136.1, 134.3, 134.2, 129.3, 
128.7, 128.6, 128.0, 127.9, 127.3, 127.2, 81.7, 81.6, 74.8, 74.7, 57.1, 57.0, 56.0, 55.9, 55.0, 54.90, 
53.9, 53.8, 45.9, 45.8, 42.6, 42.5, 40.5, 40.4, 32.0, 31.9, 30.3, 30.2, 29.8, 29.6, 29.4, 29.3, 22.3, 
22.2, 21.4, 21.3, 19.6, 19.4, 17.5, 17.3. 
 
HRMS (ESI): Calculated for C38H41N7O5S2Na
+ 762.2503 Found 762.2493.  
 
[α]D
23 − 6.97 (𝐶 0.25, CHCl3) 
 
1H NMR (900 MHz, CDCl3) δ ppm 8.21 (s, 1H), 7.94 (s, 1H), 7.28 – 
7.21 (m, 4H), 7.20 – 7.15 (m, 3H), 7.12 – 7.07 (m, 3H), 6.77 (d, J = 
7.4 Hz, 1H), 6.19 (d, J = 9.5 Hz, 1H), 5.80 (td, J = 9.6, 5.6 Hz, 1H), 
5.21 (dd, J = 9.6, 8.2 Hz, 1H), 4.74 (dq, J = 13.1, 6.1 Hz, 1H), 4.59 
(m, 1H), 4.44 (t, J = 8.3 Hz, 1H), 4.17 (d, J = 8.8 Hz, 1H), 3.56 – 3.54 
(m, 2H), 3.44 (dd, J = 14.4, 5.1 Hz, 1H), 3.16 – 3.06 (m, 2H), 2.96 
(dd, J = 14.1, 5.5 Hz, 1H), 2.29 (m, 1H), 2.23 (m, 1H), 2.03 (m, 1H), 
1.90 – 1.80 (m, 2H), 1.53 (d, J = 6.2 Hz, 3H), 1.03 (d, J = 6.7 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H). 
 
13C NMR (226 MHz, CDCl3) δ ppm 176.6, 176.5, 174.8, 174.7, 170.7, 170.6, 169.3, 169.2, 168.5, 
168.4, 161.2, 161.1, 146.4, 143.8, 135.1, 134.9, 133.6, 133.5, 132.6, 132.5, 129.7, 129.5, 129.0, 
128.3, 127.6, 127.3, 80.2, 74.5, 56.9, 56.1, 53.2, 52.7, 46.9, 38.1, 37.5, 33.6, 29.8, 29.6, 29.4, 25.6, 
21.7, 19.4, 18.7. 
 
HRMS (ESI): Calculated for C38H41N7O5S2Na
+ 762.2503 Found 762.2504. 
 
[α]D
2343.71 (𝐶 0.15, CHCl3) 
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1H NMR (900 MHz, CDCl3) δ ppm 8.23 (s, 1H), 7.90 (s, 1H), 7.33 – 
7.28 (m, 3H), 7.19 – 7.14 (m, 2H), 7.13 – 7.09 (m, 2H), 7.09 – 7.03 
(m, 3H), 6.88 (d, J = 6.5 Hz, 1H), 6.19 (d, J = 8.9 Hz, 1H), 5.69 (td, J 
= 8.9, 5.7 Hz, 1H), 5.27 (dd, J = 10.0, 8.3 Hz, 1H), 4.73 (dq, J = 11.5, 
6.5 Hz, 1H), 4.62 (m, 1H), 4.42 (dd, J = 9.5, 7.2 Hz, 1H), 4.23 – 4.15 
(m, 2H), 3.56 (m, 1H), 3.47 (dd, J = 14.3, 6.2 Hz, 1H), 3.40 (dd, J = 
14.3, 5.1 Hz, 1H), 3.15 – 3.11 (m, 2H), 3.01 (dd, J = 14.1, 4.8 Hz, 
1H), 2.27 – 2.19 (m, 2H), 2.03 (m, 1H), 1.88 – 1.85 (m, 2H), 1.66 (m, 1H), 1.51 (d, J = 6.2 Hz, 
3H), 1.02 (d, J = 6.7 Hz, 3H), 0.91 (d, J = 6.7 Hz, 3H). 
 
13C NMR (226 MHz, CDCl3) δ ppm 168.3, 168.2, 146.7, 146.6, 142.3, 142.2, 134.7, 134.6, 130.9, 
130.8, 129.9, 129.8, 129.4, 129.1, 129.0, 128.8, 128.7, 128.3, 128.2, 127.9, 127.8, 127.2, 127.1, 
79.7, 79.6,74.5, 74.4, 68.2, 68.1, 57.1, 57.0, 53.2, 53.1, 53.0, 52.8, 46.8, 46.7, 39.0, 38.9, 38.8, 
38.7, 37.2, 37.1, 34.4, 34.3, 30.4, 30.3, 29.8, 29.6, 29.4, 29.3, 29.0, 28.9, 25.7, 25.6, 23.0, 22.9, 
21.8, 21.7, 19.4, 19.3, 18.7, 18.6. 
 
HRMS (ESI): Calculated for C38H41N7O5S2Na
+ 762.2503 Found 762.2503. 
 
[α]D
2330.68 (𝐶 0.10, CHCl3)  
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6.3 Chapter 3 experimental procedures 
 
The D-threonine-L-isoleucine dipeptide (3.11) 
Commercially available D-threonine (1g, 8.4mmol) was dried under high vacuum for 2 hrs. 
Anhydrous MeOH (8mL) was added and the mixture cooled to 0oC (ice bath) with stirring. SOCl2 
(2mL) was added to the solution under argon (balloon), and stirred for 1 h at 0oC. MeOH was 
removed under high vacuum and DCM was added to the residue and again removed by vacuum 
(repeated twice). Vacuum drying gave a pale yellow oily residue of D-threonine methyl ester. 
Anhydrous DMF (8.4mL) was added in the D-threonine methyl ester (0.112g, 0.84mmol) under 
argon and then commercially available Boc-L-isoleucine 3.10 (0.194g, 0.84mmol) was added. 
The solution was cooled to 0oC, and then TMP (0.33mL, 2.52mmol) was added dropwise 
followed by COMU (0.432g, 1mmol). After 1 h, the ice bath was removed and the reaction was 
allowed to warm up to r.t. After 2 hrs the reaction was diluted with EtOAc (80mL), washed with 
1M HCl solution (2×16mL), saturated NaHCO3 solution (2×16mL), and brine solution (16mL), 
and then dried over MgSO4, filtered and evaporated. Flash chromatography (silica gel, petroleum 
ether: EtOAc 1:1, Rf=0.37) gave the pure dipeptide 3.11 as a white foam (0.185g, 64%). The 
1H 
NMR and 13C NMR spectra matched that reported in the literature.160 
 
1H NMR (400 MHz, CDCl3) δ ppm 6.96 (d, J = 8.9 Hz, 1H), 5.12 (br d, J = 5.7 Hz, 1H), 4.55 (dd, 
J = 8.9, 2.6 Hz, 1H), 4.33 (m, 1H), 4.04 (m, 1H), 3.72 (s, 3H), 2.89 (d, J = 1.2 Hz, 1H), 1.90 (m, 
1H), 1.49 (m, 1H), 1.41 (s, 9H), 1.19 (d, J = 6.4 Hz, 3H), 1.11 (m, 1H), 0.94 (d, J = 6.8 Hz, 3H), 
0.88 (t, J = 7.4 Hz, 3H). 
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13C NMR (100 MHz, CDCl3) δ ppm 172.2, 171.4, 155.9, 80.1, 67.7, 59.5, 57.2, 52.5, 37.1, 28.3, 
24.5, 20.0, 15.7, 11.5. 
 
 
The tetrapeptide (3.13) 
The synthesised dipeptide 3.11 (0.159g, 0.46mmol) was dissolved in a mixture of THF (3.3mL), 
MeOH (3.3mL) and H2O (1.7mL). 1M NaOH solution (0.7mL) was added dropwise to the 
reaction, and stirred at r.t. After 2 hrs, MeOH and THF were removed under vacuum. The residue 
was diluted with H2O (8mL). The aqueous phase was acidified with 10% citric acid solution to 
pH3, and extracted with EtOAc (3×12mL). The combined organic phase was washed with H2O 
(12mL) and brine (12mL), dried over Na2SO4 and evaporated giving crude dipeptide carboxylic 
acid as a pale yellow oily residue. The residue was dissolved in anhydrous DMF (3.4mL) and 
valine thiazole amine salt (0.077g, 0.337mmol) was added. The mixture was cooled to 0oC, and 
TMP (0.134mL, 1.011mmol) was added to the solution dropwise, followed by COMU (0.174g, 
0.404mmol). After 1 hr at 0oC, and then the ice bath was removed and the reaction was allowed to 
warm up to r.t. After 2 hrs, the reaction mixture was diluted with EtOAc (36mL), washed with 1M 
HCl solution (2×7mL), saturated NaHCO3 solution  (2×7mL), brine solution (7mL), dried over 
MgSO4, filtered and evaporated. Flash chromatography (silica gel, petroleum ether: EtOAc 1:1, 
Rf=0.47) gave the pure tetrapeptide 3.13 as a white foam (0.111g, 61%). 
 
1H NMR (500 MHz, CDCl3) δ ppm 8.26 (s, 1H), 7.56 (d, J = 8.5 Hz, 1H), 7.12 (d, J = 7.5 Hz, 
1H), 5.22 (d, J = 10.3 Hz, 1H), 5.13 (m, 1H), 4.45 (d, J = 7.5 Hz, 1H), 4.40 (d, J = 6.5 Hz, 1H), 
4.34 (dd, J = 7.2, 3.1 Hz, 2H), 2.32 (m, 1H), 1.84 (m, 1H), 1.44 (m, 2H), 1.38 (s, 9H), 1.32 (t, J = 
7.1 Hz, 3H), 1.15 (d, J = 6.5 Hz, 3H), 1.11 (d, J = 6.5 Hz, 3H), 0.98 – 0.81 (m, 9H). 
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13C NMR (125 MHz, CDCl3) δ ppm 176.7, 176.6, 173.3, 173.2, 148.1, 147.8, 80.1, 66.4, 66.1, 
61.6, 57.8, 57.7, 57.1, 56.9, 37.4, 37.2, 33.1, 28.3, 24.8, 24.7, 19.3, 18.4, 18.2, 17.6, 17.4, 15.7, 
14.2, 11.4. 
 
HRMS (ESI): Calculated for C25H42N4O7SNa
+ 565.2666 Found 565.2667. 
 
 
The tetrapeptide with an oxazoline ring (3.14) 
The tetrapeptide 3.13 (10mg, 0.0184mmol), dried under high vacuum, was dissolved in anhydrous 
DCM (0.2mL) under argon. The solution was cooled to -17oC (salt-ice bath) before addition of 
Deoxo-Fluor (0.004mL, 0.02mmol). After stirring for 10min, the reaction was placed in the 
freezer (-24oC). On completion (monitored by TLC, 2 days), the solution was treated with 
saturated NaHCO3 solution (0.5mL) at -17
oC (salt-ice bath). The salt-ice bath was removed and 
the reaction was allowed to warm up to r.t. at which point more saturated NaHCO3 solution 
(0.5mL) was added. The reaction mixture was then diluted with EtOAc (1mL) and dried over 
MgSO4, filtered and evaporated. Flash chromatography (silica gel, petroleum ether: EtOAc 1:1, 
Rf=0.75) gave the pure tetrapeptide 3.14 as a white foam (8.4mg, 87%). 
 
1H NMR (400 MHz, CDCl3) δ ppm 8.26 (s, 1H), 7.34 (d, J = 9.0 Hz, 1H), 5.18 (dd, J = 9.0, 5.7 
Hz, 1H), 5.03 (m, 2H), 4.97 (m, 1H), 4.73 (d, J = 10.7 Hz, 1H), 4.38 (m, 1H), 4.33 (q, J = 7.1 Hz, 
2H), 2.41 (m, 1H), 1.84 (m, 2H), 1.43 (s, 9H), 1.35 (t, J = 7.1 Hz, 3H), 1.22 (d, J = 6.6 Hz, 3H), 
0.95 (td, J = 14.4, 7.2 Hz, 12H). 
 
13C NMR (100MHz, CDCl3) δ ppm 169.5, 161.2, 148.3, 129.1, 79.5, 71.1, 61.6, 56.3, 33.1, 28.4, 
25.0, 19.3, 17.5, 16.4, 15.5, 14.3. 
 
HRMS (ESI): Calculated for C25H40N4O6S Na
+ 547.2561 Found 547.2566. 
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The epimerized tetrapeptide (3.15) 
The tetrapeptide 3.14 (12mg, 0.023mmol), dried under high vacuum, was dissolved in anhydrous 
ethanol (2.5mL) under argon. Fresh prepared sodium ethoxide solution (14mM, 0.2mL) was then 
added to the reaction. After 1 hr at reflux, the reaction was cooled to r.t. The solvent was then 
removed and the crude dried under high vacuum. Flash chromatography (silica gel, petroleum 
ether: EtOAc 2:1, Rf=0.5) gave a mixture of two diastereomers 3.15a and 3.15b of the 
tetrapeptides as a white foam (10.6mg, 88%), which was separated by normal phase HPLC 
(hexane: EtOAc 2:1, Rf=0.5) to give enantiomeric pure diastereomers 3.15a and 3.15b. Column: 
Phenomenex Luna 5u Silica (2) 100A column, 250 x 4.6mm; Condition: hexane (A) & EtOAc (B) 
gradient; starting at 40% (B) then to 65% (B) in 15 min. Major peaks eluted at 6.7 and 9.7 min. 
 
1H NMR (400 MHz, CDCl3) δ ppm 8.31 (s, 1H), 7.21 (d, J = 9.1 
Hz, 1H), 5.14 (dd, J = 9.1, 5.9 Hz, 1H), 5.07 (d, J = 8.1 Hz, 1H), 
4.75 (m, 1H), 4.34 (q, J = 7.1 Hz, 2H), 4.16 (d, J = 7.8 Hz, 1H), 
2.38 (m, 1H), 1.88 – 1.75 (m, 2H), 1.73 – 1.55 (m, 2H), 1.48 (d, J 
= 6.3 Hz, 3H), 1.44 (s, 9H), 1.35 (t, J = 7.1 Hz, 3H), 0.97 – 0.85 
(m, 12H). 
 
13C NMR (100 MHz, CDCl3) δ ppm 176.2, 171.2, 169.0, 161.2, 155.2, 148.3, 129.2, 80.5, 79.9, 
75.2, 74.5, 61.7, 60.4, 60.2, 56.1, 53.4, 40.8, 38.3, 33.7, 33.1, 29.7, 28.3, 25.0, 23.0, 21.9, 21.0, 
20.6, 19.2, 17.5, 17.4, 15.2, 14.3, 14.2, 14.0, 12.6, 11.5. 
 
HRMS (ESI): Calculated for C25H40N4O6SNa
+ 547.2561 Found 524.2549. 
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1H NMR (400 MHz, CDCl3) δ ppm 8.26 (s, 1H), 7.25 (d, J = 8.0 
Hz, 1H), 5.15 (dd, J = 9.0, 5.8 Hz, 1H), 5.11 (d, J = 8.5 Hz, 1H), 
4.71 (m, 1H), 4.32 (q, J = 7.1 Hz, 2H), 4.20 (d, J = 7.7 Hz, 1H), 
2.39 (m, 1H), 1.86 –1.75 (m, 2H), 1.73 – 1.53 (m, 2H), 1.48 (d, J 
= 6.2 Hz, 3H), 1.43 (s, 9H), 1.34 (t, J = 7.1 Hz, 3H), 0.97 (dd, J = 
6.8, 3.6 Hz, 6H), 0.88 (d, J = 6.8 Hz, 3H), 0.86 (t, J = 7.4 Hz, 3H). 
 
13C NMR (100 MHz, CDCl3) δ ppm 176.3, 171.3, 169.4, 161.1, 155.3, 148.2, 129.1, 80.5, 79.9, 
74.4, 61.6, 56.4, 53.4, 38.3, 33.2, 29.7, 28.3, 24.9, 21.8, 19.3, 17.7, 15.1, 14.3, 11.6. 
 
HRMS (ESI): Calculated for C25H40N4O6SNa
+ 547.2561 Found 524.2549 
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6.4  Chapter 4 experimental procedures 
6.4.1 Experimental for circular dichroism 
The ligand, block B (2.49a) (3.03mg, 0.005 mmol) was dissolved in MeOH (5 mL) (ligand 
solution, 1 mM, 1 equivalent = 700μL). The metal Cu(II) ion solution (25 mM, 1 equivalent = 
28μL) was made by dissolving Cu(OTf)2 (0.904g, 2.50 mmol) in MeOH (100 mL). The base 
(n-Bu4N)(OMe) was dissolved in MeOH to be solution (25 mM, 1 equivalent = 28μL).  
 
Initially, the ligand solution (700μL) was prepared using calibrated automatic pipettes and added 
to a 10 mm quartz cell. The solution was mixed by inverting the stoppered cell several times. 
After the CD of the ligand solution was measured, the titrations of Cu(II) ion solution was 
performed in the range of 0.2 to 2 equivalents in 0.2 equivalent steps to the ligand solution. 
Titrations of the base solution to the solution of ligand (1 equivalent) and Cu(II) ion (2 
equivalents) was performed in the range of 0.2 to 6 equivalent in 0.2 equivalent steps. 
6.4.2 Experiment for mass spectrometry 
A HI-lissoclinamide 5 (1.143) solution in MeOH (10μM) was prepared along with various metal 
salt solutions in MeOH including: Copper (II) triflate solution (100μM), zinc acetate solution 
(100μM), and calcium carbonate solution (100μM) and various halogen salt solutions in MeOH 
including sodium fluoride solution (100μM), sodium chloride solution (100μM), sodium bromide 
solution (100μM), and sodium iodide solution (100μM). 
6.4.3 Experimental for biological studies involving cancer cell lines 
The four diastereomers of HI-lissoclinamide 5 (1.143) were dissolved in DMSO and diluted in 
culture medium (RPMI 1640-10% fetal calf serum). Cells were seeded in microtitre plates 
(2000-5000 cells/well) in triplicate and treated with the compounds. After 6-7 days culture, 
adherent cell lines were fixed in ethanol, stained with sulforhodamine B. The absorbance at 540 
nm was plotted as % untreated cells vs dose and the IC50 (dose causing 50% inhibition of growth) 
was interpolated. The non-adherent (K562) or partly-adherent (Colo-205) cells were treated in 
situ with 10μl per well of CellTiter 96 reagent (Promega), incubated for 2 h and the absorbance 
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read at 490 nm.172  
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Appendix A  Chapter 2 spectra 
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Appendix B  Chapter 3 spectra 
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